• Images
• Videos
• Documents
• Books
• Articles

Biological activity

See also: Pharmacodynamics of progesterone § Mechanism of action

Progesterone is the most important progestogen in the body. As a potent agonist of the nuclear progesterone receptor (nPR) (with an affinity of KD = 1 nM) the resulting effects on ribosomal transcription plays a major role in regulation of female reproduction.⁷⁸ In addition, progesterone is an agonist of the more recently discovered membrane progesterone receptors (mPRs),⁹ of which the expression has regulation effects in reproduction function (oocyte maturation, labor, and sperm motility) and cancer although additional research is required to further define the roles.¹⁰ It also functions as a ligand of the PGRMC1 (progesterone receptor membrane component 1) which impacts tumor progression, metabolic regulation, and viability control of nerve cells.¹¹¹²¹³ Moreover, progesterone is also known to be an antagonist of the sigma σ1 receptor,¹⁴¹⁵ a negative allosteric modulator of nicotinic acetylcholine receptors,¹⁶ and a potent antagonist of the mineralocorticoid receptor (MR).¹⁷ Progesterone prevents MR activation by binding to this receptor with an affinity exceeding even those of aldosterone and glucocorticoids such as cortisol and corticosterone,¹⁸ and produces antimineralocorticoid effects, such as natriuresis, at physiological concentrations.¹⁹ In addition, progesterone binds to and behaves as a partial agonist of the glucocorticoid receptor (GR), albeit with very low potency (EC50 >100-fold less relative to cortisol).²⁰²¹

Progesterone, through its neurosteroid active metabolites such as 5α-dihydroprogesterone and allopregnanolone, acts indirectly as a positive allosteric modulator of the GABAA receptor.²²

Progesterone and some of its metabolites, such as 5β-dihydroprogesterone, are agonists of the pregnane X receptor (PXR),²³ albeit weakly so (EC50 >10 μM).²⁴ In accordance, progesterone induces several hepatic cytochrome P450 enzymes,²⁵ such as CYP3A4,²⁶²⁷ especially during pregnancy when concentrations are much higher than usual.²⁸ Perimenopausal women have been found to have greater CYP3A4 activity relative to men and postmenopausal women, and it has been inferred that this may be due to the higher progesterone levels present in perimenopausal women.²⁹

Progesterone modulates the activity of CatSper (cation channels of sperm) voltage-gated Ca2+ channels. Since eggs release progesterone, sperm may use progesterone as a homing signal to swim toward eggs (chemotaxis). As a result, it has been suggested that substances that block the progesterone binding site on CatSper channels could potentially be used in male contraception.³⁰³¹

Biological function

Hormonal interactions

Progesterone has a number of physiological effects that are amplified in the presence of estrogens. Estrogens through estrogen receptors (ERs) induce or upregulate the expression of the PR.³² One example of this is in breast tissue, where estrogens allow progesterone to mediate lobuloalveolar development.³³³⁴³⁵

Elevated levels of progesterone potently reduce the sodium-retaining activity of aldosterone, resulting in natriuresis and a reduction in extracellular fluid volume. Progesterone withdrawal, on the other hand, is associated with a temporary increase in sodium retention (reduced natriuresis, with an increase in extracellular fluid volume) due to the compensatory increase in aldosterone production, which combats the blockade of the mineralocorticoid receptor by the previously elevated level of progesterone.³⁶

Early sexual differentiation

Placental progesterone can be converted into 5α-dihydrotestosterone (DHT), a potent androgen that is responsible for the development of male genitalia.³⁷ This can be done both by conversion into testosterone, which is then converted to DHT, and via the androgen backdoor pathway, which is particularly important for fetal development.³⁸ As progesterone is the precursor for both pathways, it plays a key role in sexual differentiation.³⁹⁴⁰

Reproductive system

Progesterone has key effects via non-genomic signalling on human sperm as they migrate through the female reproductive tract before fertilization occurs, though the receptor(s) as yet remain unidentified.⁴¹ Detailed characterisation of the events occurring in sperm in response to progesterone has elucidated certain events including intracellular calcium transients and maintained changes,⁴² slow calcium oscillations,⁴³ now thought to possibly regulate motility.⁴⁴ It is produced by the ovaries.⁴⁵ Progesterone has also been shown to demonstrate effects on octopus spermatozoa.⁴⁶

Progesterone is sometimes called the "hormone of pregnancy",⁴⁷ and it has many roles relating to the development of the fetus:

• Progesterone converts the endometrium to its secretory stage to prepare the uterus for implantation. At the same time progesterone affects the vaginal epithelium and cervical mucus, making it thick and impenetrable to sperm. Progesterone is anti-mitogenic in endometrial epithelial cells, and as such, mitigates the tropic effects of estrogen.⁴⁸ If pregnancy does not occur, progesterone levels will decrease, leading to menstruation. Normal menstrual bleeding is progesterone-withdrawal bleeding. If ovulation does not occur and the corpus luteum does not develop, levels of progesterone may be low, leading to anovulatory dysfunctional uterine bleeding.
• During implantation and gestation, progesterone appears to decrease the maternal immune response to allow for the acceptance of the pregnancy.⁴⁹
• Progesterone decreases contractility of the uterine smooth muscle.⁵⁰ This effect contributes to prevention of preterm labor.⁵¹ Studies have shown that in individuals who are pregnant with a single fetus, asymptomatic in the prenatal stage, and at a high risk of giving pre-term birth spontaneously, vaginal progesterone medication has been found to be effective in preventing spontaneous pre-term birth. Individuals who are at a high risk of giving pre-term birth spontaneously are those who have a short cervix of less than 25 mm or have previously given pre-term birth spontaneously. Although pre-term births are generally considered to be less than 37 weeks, these studies found that vaginal progesterone is associated with fewer pre-term births of less than 34 weeks.⁵²
• A drop in progesterone levels is possibly one step that facilitates the onset of labor.
• In addition, progesterone inhibits lactation during pregnancy. The fall in progesterone levels following delivery is one of the triggers for milk production.

The fetus metabolizes placental progesterone in the production of adrenal steroids.⁵³

Breasts

See also: Breast development § Biochemistry

Lobuloalveolar development

Progesterone plays an important role in breast development. In conjunction with prolactin, it mediates lobuloalveolar maturation of the mammary glands during pregnancy to allow for milk production and thus lactation and breastfeeding of offspring following parturition (childbirth).⁵⁴ Estrogen induces expression of the PR in breast tissue and hence progesterone is dependent on estrogen to mediate lobuloalveolar development.⁵⁵⁵⁶⁵⁷ It has been found that RANKLTooltip Receptor activator of nuclear factor kappa-B ligand is a critical downstream mediator of progesterone-induced lobuloalveolar maturation.⁵⁸ RANKL knockout mice show an almost identical mammary phenotype to PR knockout mice, including normal mammary ductal development but complete failure of the development of lobuloalveolar structures.⁵⁹

Ductal development

Though to a far lesser extent than estrogen, which is the major mediator of mammary ductal development (via the ERα),⁶⁰⁶¹ progesterone may be involved in ductal development of the mammary glands to some extent as well.⁶² PR knockout mice or mice treated with the PR antagonist mifepristone show delayed although otherwise normal mammary ductal development at puberty.⁶³ In addition, mice modified to have overexpression of PRA display ductal hyperplasia,⁶⁴ and progesterone induces ductal growth in the mouse mammary gland.⁶⁵ Progesterone mediates ductal development mainly via induction of the expression of amphiregulin, the same growth factor that estrogen primarily induces the expression of to mediate ductal development.⁶⁶ These animal findings suggest that, while not essential for full mammary ductal development, progesterone seems to play a potentiating or accelerating role in estrogen-mediated mammary ductal development.⁶⁷

Breast cancer risk

Progesterone also appears to be involved in the pathophysiology of breast cancer, though its role, and whether it is a promoter or inhibitor of breast cancer risk, has not been fully elucidated.⁶⁸⁶⁹ Most progestins, or synthetic progestogens, like medroxyprogesterone acetate, have been found to increase the risk of breast cancer in postmenopausal people in combination with estrogen as a component of menopausal hormone therapy.⁷⁰⁷¹ The combination of natural oral progesterone or the atypical progestin dydrogesterone with estrogen has been associated with less risk of breast cancer than progestins plus estrogen.⁷²⁷³⁷⁴ However, this may simply be an artifact of the low progesterone levels produced with oral progesterone.⁷⁵⁷⁶ More research is needed on the role of progesterone in breast cancer.⁷⁷

Skin health

The estrogen receptor, as well as the progesterone receptor, have been detected in the skin, including in keratinocytes and fibroblasts.⁷⁸⁷⁹ At menopause and thereafter, decreased levels of female sex hormones result in atrophy, thinning, and increased wrinkling of the skin and a reduction in skin elasticity, firmness, and strength.⁸⁰⁸¹ These skin changes constitute an acceleration in skin aging and are the result of decreased collagen content, irregularities in the morphology of epidermal skin cells, decreased ground substance between skin fibers, and reduced capillaries and blood flow.⁸²⁸³ The skin also becomes more dry during menopause, which is due to reduced skin hydration and surface lipids (sebum production).⁸⁴ Along with chronological aging and photoaging, estrogen deficiency in menopause is one of the three main factors that predominantly influences skin aging.⁸⁵

Hormone replacement therapy, consisting of systemic treatment with estrogen alone or in combination with a progestogen, has well-documented and considerable beneficial effects on the skin of postmenopausal people.⁸⁶⁸⁷ These benefits include increased skin collagen content, skin thickness and elasticity, and skin hydration and surface lipids.⁸⁸⁸⁹ Topical estrogen has been found to have similar beneficial effects on the skin.⁹⁰ In addition, a study has found that topical 2% progesterone cream significantly increases skin elasticity and firmness and observably decreases wrinkles in peri- and postmenopausal people.⁹¹ Skin hydration and surface lipids, on the other hand, did not significantly change with topical progesterone.⁹²

These findings suggest that progesterone, like estrogen, also has beneficial effects on the skin, and may be independently protective against skin aging.⁹³

Sexuality

Libido

See also: Sexual motivation and hormones

Progesterone and its neurosteroid active metabolite allopregnanolone appear to be importantly involved in libido in females.⁹⁴

Homosexuality

Dr. Diana Fleischman, of the University of Portsmouth, and colleagues looked for a relationship between progesterone and sexual attitudes in 92 women. Their research, published in the Archives of Sexual Behavior found that women who had higher levels of progesterone scored higher on a questionnaire measuring homoerotic motivation. They also found that men who had high levels of progesterone were more likely to have higher homoerotic motivation scores after affiliative priming compared to men with low levels of progesterone.^95969798

Nervous system

Progesterone, like pregnenolone and dehydroepiandrosterone (DHEA), belongs to an important group of endogenous steroids called neurosteroids. It can be metabolized within all parts of the central nervous system.⁹⁹

Neurosteroids are neuromodulators, and are neuroprotective, neurogenic, and regulate neurotransmission and myelination.¹⁰⁰ The effects of progesterone as a neurosteroid are mediated predominantly through its interactions with non-nuclear PRs, namely the mPRs and PGRMC1, as well as certain other receptors, such as the σ1 and nACh receptors.¹⁰¹

Brain damage

See also: Progesterone (medication) § Other uses

Previous studies have shown that progesterone supports the normal development of neurons in the brain, and that the hormone has a protective effect on damaged brain tissue. It has been observed in animal models that females have reduced susceptibility to traumatic brain injury and this protective effect has been hypothesized to be caused by increased circulating levels of estrogen and progesterone in females.¹⁰²

Proposed mechanism

The mechanism of progesterone protective effects may be the reduction of inflammation that follows brain trauma and hemorrhage.¹⁰³¹⁰⁴

Damage incurred by traumatic brain injury is believed to be caused in part by mass depolarization leading to excitotoxicity. One way in which progesterone helps to alleviate some of this excitotoxicity is by blocking the voltage-dependent calcium channels that trigger neurotransmitter release.¹⁰⁵ It does so by manipulating the signaling pathways of transcription factors involved in this release. Another method for reducing the excitotoxicity is by up-regulating the GABAA, a widespread inhibitory neurotransmitter receptor.¹⁰⁶

Progesterone has also been shown to prevent apoptosis in neurons, a common consequence of brain injury. It does so by inhibiting enzymes involved in the apoptosis pathway specifically concerning the mitochondria, such as activated caspase 3 and cytochrome c.¹⁰⁷

Not only does progesterone help prevent further damage, it has also been shown to aid in neuroregeneration.¹⁰⁸ One of the serious effects of traumatic brain injury includes edema. Animal studies show that progesterone treatment leads to a decrease in edema levels by increasing the concentration of macrophages and microglia sent to the injured tissue.¹⁰⁹¹¹⁰ This was observed in the form of reduced leakage from the blood brain barrier in secondary recovery in progesterone treated rats. In addition, progesterone was observed to have antioxidant properties, reducing the concentration of oxygen free radicals faster than without.¹¹¹ There is also evidence that the addition of progesterone can also help remyelinate damaged axons due to trauma, restoring some lost neural signal conduction.¹¹² Another way progesterone aids in regeneration includes increasing the circulation of endothelial progenitor cells in the brain. This helps new vasculature to grow around scar tissue which helps repair the area of insult.¹¹³

Addiction

Progesterone enhances the function of serotonin receptors in the brain, so an excess or deficit of progesterone has the potential to result in significant neurochemical issues. This provides an explanation for why some people resort to substances that enhance serotonin activity such as nicotine, alcohol, and cannabis when their progesterone levels fall below optimal levels.¹¹⁴

• Sex differences in hormone levels may induce women to respond differently than men to nicotine. When women undergo cyclic changes or different hormonal transition phases (menopause, pregnancy, adolescence), there are changes in their progesterone levels.¹¹⁵ Therefore, females have an increased biological vulnerability to nicotine's reinforcing effects compared to males and progesterone may be used to counter this enhanced vulnerability. This information supports the idea that progesterone can affect behavior.¹¹⁶
• Similar to nicotine, cocaine also increases the release of dopamine in the brain. The neurotransmitter is involved in the reward center and is one of the main neurotransmitters involved with substance abuse and reliance. In a study of cocaine users, it was reported that progesterone reduced craving and the feeling of being stimulated by cocaine. Thus, progesterone was suggested as an agent that decreases cocaine craving by reducing the dopaminergic properties of the drug.¹¹⁷

Societal

In a 2012 University of Amsterdam study of 120 women, women's luteal phase (higher levels of progesterone, and increasing levels of estrogen) was correlated with a lower level of competitive behavior in gambling and math contest scenarios, while their premenstrual phase (sharply-decreasing levels of progesterone, and decreasing levels of estrogen) was correlated with a higher level of competitive behavior.¹¹⁸

Other effects

• Progesterone also has a role in skin elasticity and bone strength, in respiration, in nerve tissue and in female sexuality, and the presence of progesterone receptors in certain muscle and fat tissue may hint at a role in sexually dimorphic proportions of those.¹¹⁹
• During pregnancy, progesterone is said to decrease uterine irritability.¹²⁰
• During pregnancy, progesterone helps to suppress immune responses of the mother to fetal antigens, which prevents rejection of the fetus.¹²¹
• Progesterone raises epidermal growth factor-1 (EGF-1) levels, a factor often used to induce proliferation, and used to sustain cultures, of stem cells.¹²²
• Progesterone increases core temperature (thermogenic function) during ovulation.¹²³¹²⁴
• Progesterone reduces spasm and relaxes smooth muscle. Bronchi are widened and mucus regulated. (PRs are widely present in submucosal tissue.)
• Progesterone acts as an antiinflammatory agent and regulates the immune response.
• Progesterone reduces gall-bladder activity.¹²⁵
• Progesterone normalizes blood clotting and vascular tone, zinc and copper levels, cell oxygen levels, and use of fat stores for energy.
• Progesterone may affect gum health, increasing risk of gingivitis (gum inflammation).¹²⁶
• Progesterone appears to prevent endometrial cancer (involving the uterine lining) by regulating the effects of estrogen.
• Progesterone plays an important role in the signaling of insulin release and pancreatic function, and may affect the susceptibility to diabetes or gestational diabetes.¹²⁷¹²⁸
• Progesterone levels in the blood were found to be lower in those who had higher weight and higher BMI among those who became pregnant through in vitro fertilization.¹²⁹
• Current data shows that micronized progesterone, which is chemically identical to the progesterone produced in people's bodies, in combination with estrogen in menopausal hormone therapy does not seem to have significant effects on venous thromboembolism (blood clots in veins) and ischemic stroke (lack of blood flow to the brain due to blockage of a blood vessel that supplies the brain). However, more studies need to be conducted to see whether or not micronized progesterone alone or in combined menopausal hormone therapy changes the risk of myocardial infarctions (heart attacks).¹³⁰
• There have not been any studies done yet on the effects of micronized progesterone on hair loss due to menopause.¹³¹
• Despite suggestions for using hormone therapy to prevent loss of muscle mass in post-menopausal individuals (50 and older), menopausal hormone therapy involving either estrogen alone or estrogen and progesterone has not been found to preserve muscle mass.¹³² Menopausal hormone therapy also does not result in body weight reduction, BMI reduction, or change in glucose metabolism.¹³³

Biochemistry

Biosynthesis

In mammals, progesterone, like all other steroid hormones, is synthesized from pregnenolone, which itself is derived from cholesterol.

Cholesterol undergoes double oxidation to produce 22R-hydroxycholesterol and then 20α,22R-dihydroxycholesterol. This vicinal diol is then further oxidized with loss of the side chain starting at position C22 to produce pregnenolone. This reaction is catalyzed by cytochrome P450scc.

The conversion of pregnenolone to progesterone takes place in two steps. First, the 3β-hydroxyl group is oxidized to a keto group and second, the double bond is moved to C4, from C5 through a keto/enol tautomerization reaction.¹³⁴ This reaction is catalyzed by 3β-hydroxysteroid dehydrogenase/δ5-4-isomerase.

Progesterone in turn is the precursor of the mineralocorticoid aldosterone, and after conversion to 17α-hydroxyprogesterone, of cortisol and androstenedione. Androstenedione can be converted to testosterone, estrone, and estradiol, highlighting the critical role of progesterone in testosterone synthesis.

Pregnenolone and progesterone can also be synthesized by yeast.¹³⁵

Approximately 30 mg of progesterone is secreted from the ovaries per day in reproductive-age women, while the adrenal glands produce about 1 mg of progesterone per day.¹³⁶

• v
• t
• e

Distribution

Progesterone binds extensively to plasma proteins, including albumin (50–54%) and transcortin (43–48%).¹³⁷ It has similar affinity for albumin relative to the PR.¹³⁸

Metabolism

The metabolism of progesterone is rapid and extensive and occurs mainly in the liver,^139140141 though enzymes that metabolize progesterone are also expressed widely in the brain, skin, and various other extrahepatic tissues.¹⁴²¹⁴³ Progesterone has an elimination half-life of only approximately 5 minutes in circulation.¹⁴⁴ The metabolism of progesterone is complex, and it may form as many as 35 different unconjugated metabolites when it is ingested orally.¹⁴⁵¹⁴⁶ Progesterone is highly susceptible to enzymatic reduction via reductases and hydroxysteroid dehydrogenases due to its double bond (between the C4 and C5 positions) and its two ketones (at the C3 and C20 positions).¹⁴⁷

The major metabolic pathway of progesterone is reduction by 5α-reductase¹⁴⁸ and 5β-reductase into the dihydrogenated 5α-dihydroprogesterone and 5β-dihydroprogesterone, respectively.^149150151152 This is followed by the further reduction of these metabolites via 3α-hydroxysteroid dehydrogenase and 3β-hydroxysteroid dehydrogenase into the tetrahydrogenated allopregnanolone, pregnanolone, isopregnanolone, and epipregnanolone.^153154155156 Subsequently, 20α-hydroxysteroid dehydrogenase and 20β-hydroxysteroid dehydrogenase reduce these metabolites to form the corresponding hexahydrogenated pregnanediols (eight different isomers in total),¹⁵⁷¹⁵⁸ which are then conjugated via glucuronidation and/or sulfation, released from the liver into circulation, and excreted by the kidneys into the urine.¹⁵⁹¹⁶⁰ The major metabolite of progesterone in the urine is the 3α,5β,20α isomer of pregnanediol glucuronide, which has been found to constitute 15 to 30% of an injection of progesterone.¹⁶¹¹⁶² Other metabolites of progesterone formed by the enzymes in this pathway include 3α-dihydroprogesterone, 3β-dihydroprogesterone, 20α-dihydroprogesterone, and 20β-dihydroprogesterone, as well as various combination products of the enzymes aside from those already mentioned.^163164165166 Progesterone can also first be hydroxylated (see below) and then reduced.¹⁶⁷ Endogenous progesterone is metabolized approximately 50% into 5α-dihydroprogesterone in the corpus luteum, 35% into 3β-dihydroprogesterone in the liver, and 10% into 20α-dihydroprogesterone.¹⁶⁸

Relatively small portions of progesterone are hydroxylated via 17α-hydroxylase (CYP17A1) and 21-hydroxylase (CYP21A2) into 17α-hydroxyprogesterone and 11-deoxycorticosterone (21-hydroxyprogesterone), respectively,¹⁶⁹ and pregnanetriols are formed secondarily to 17α-hydroxylation.¹⁷⁰¹⁷¹ Even smaller amounts of progesterone may be also hydroxylated via 11β-hydroxylase (CYP11B1) and to a lesser extent via aldosterone synthase (CYP11B2) into 11β-hydroxyprogesterone.^172173174 In addition, progesterone can be hydroxylated in the liver by other cytochrome P450 enzymes which are not steroid-specific.¹⁷⁵ 6β-Hydroxylation, which is catalyzed mainly by CYP3A4, is the major transformation, and is responsible for approximately 70% of cytochrome P450-mediated progesterone metabolism.¹⁷⁶ Other routes include 6α-, 16α-, and 16β-hydroxylation.¹⁷⁷ However, treatment of women with ketoconazole, a strong CYP3A4 inhibitor, had minimal effects on progesterone levels, producing only a slight and non-significant increase, and this suggests that cytochrome P450 enzymes play only a small role in progesterone metabolism.¹⁷⁸

Levels

Progesterone levels are relatively low during the preovulatory phase of the menstrual cycle, rise after ovulation, and are elevated during the luteal phase, as shown in the diagram above. Progesterone levels tend to be less than 2 ng/mL prior to ovulation and greater than 5 ng/mL after ovulation. If pregnancy occurs, human chorionic gonadotropin is released, maintaining the corpus luteum and allowing it to maintain levels of progesterone. Between 7 and 9 weeks, the placenta begins to produce progesterone in place of the corpus luteum in a process called the luteal-placental shift.¹⁸⁰

After the luteal-placental shift, progesterone levels start to rise further and may reach 100 to 200 ng/mL at term. Whether a decrease in progesterone levels is critical for the initiation of labor has been argued and may be species-specific. After delivery of the placenta and during lactation, progesterone levels are very low.

Progesterone levels are low in children and postmenopausal people.¹⁸¹ Adult males have levels similar to those in women during the follicular phase of the menstrual cycle.

Ranges

Blood test results should always be interpreted using the reference ranges provided by the laboratory that performed the results. Example reference ranges are listed below.

Sources

Animal

Progesterone is produced in high amounts in the ovaries (by the corpus luteum) from the onset of puberty to menopause, and is also produced in smaller amounts by the adrenal glands after the onset of adrenarche in both males and females. To a lesser extent, progesterone is produced in nervous tissue, especially in the brain, and in adipose (fat) tissue, as well.

During human pregnancy, progesterone is produced in increasingly high amounts by the ovaries and placenta. At first, the source is the corpus luteum that has been "rescued" by the presence of human chorionic gonadotropin (hCG) from the conceptus. However, after the 8th week, production of progesterone shifts to the placenta. The placenta utilizes maternal cholesterol as the initial substrate, and most of the produced progesterone enters the maternal circulation, but some is picked up by the fetal circulation and used as substrate for fetal corticosteroids. At term the placenta produces about 250 mg progesterone per day.

An additional animal source of progesterone is milk products. After consumption of milk products the level of bioavailable progesterone goes up.²⁰⁸

Plants

In at least one plant, Juglans regia, progesterone has been detected.²⁰⁹ In addition, progesterone-like steroids are found in Dioscorea mexicana. Dioscorea mexicana is a plant that is part of the yam family native to Mexico.²¹⁰ It contains a steroid called diosgenin that is taken from the plant and is converted into progesterone.²¹¹ Diosgenin and progesterone are also found in other Dioscorea species, as well as in other plants that are not closely related, such as fenugreek.

Another plant that contains substances readily convertible to progesterone is Dioscorea pseudojaponica native to Taiwan. Research has shown that the Taiwanese yam contains saponins — steroids that can be converted to diosgenin and thence to progesterone.²¹²

Many other Dioscorea species of the yam family contain steroidal substances from which progesterone can be produced. Among the more notable of these are Dioscorea villosa and Dioscorea polygonoides. One study showed that the Dioscorea villosa contains 3.5% diosgenin.²¹³ Dioscorea polygonoides has been found to contain 2.64% diosgenin as shown by gas chromatography-mass spectrometry.²¹⁴ Many of the Dioscorea species that originate from the yam family grow in countries that have tropical and subtropical climates.²¹⁵

Medical use

Main articles: Progesterone (medication), Pharmacodynamics of progesterone, and Pharmacokinetics of progesterone

Progesterone is used as a medication. It is used in combination with estrogens mainly in hormone therapy for menopausal symptoms and low sex hormone levels.²¹⁶²¹⁷ It may also be used alone to treat menopausal symptoms. Studies have shown that transdermal progesterone (skin patch) and oral micronized progesterone are effective treatments for certain symptoms of menopause such as hot flashes and night sweats, which are otherwise referred to as vasomotor symptoms or VMS.²¹⁸

It is also used to support pregnancy and fertility and to treat gynecological disorders.^219220221222 Progesterone has been shown to prevent miscarriage in those with 1) vaginal bleeding early in their current pregnancy and 2) a previous history of miscarriage.²²³ Progesterone can be taken by mouth, through the vagina, and by injection into muscle or fat, among other routes.²²⁴

Chemistry

See also: List of neurosteroids

Progesterone is a naturally occurring pregnane steroid and is also known as pregn-4-ene-3,20-dione.²²⁵²²⁶ It has a double bond (4-ene) between the C4 and C5 positions and two ketone groups (3,20-dione), one at the C3 position and the other at the C20 position.²²⁷²²⁸

Synthesis

Progesterone is commercially produced by semisynthesis. Two main routes are used: one from yam diosgenin first pioneered by Marker in 1940, and one based on soy phytosterols scaled up in the 1970s. Additional (not necessarily economical) semisyntheses of progesterone have also been reported starting from a variety of steroids. For the example, cortisone can be simultaneously deoxygenated at the C-17 and C-21 position by treatment with iodotrimethylsilane in chloroform to produce 11-keto-progesterone (ketogestin), which in turn can be reduced at position-11 to yield progesterone.²²⁹

Marker semisynthesis

Main article: Marker degradation

An economical semisynthesis of progesterone from the plant steroid diosgenin isolated from yams was developed by Russell Marker in 1940 for the Parke-Davis pharmaceutical company.²³⁰ This synthesis is known as the Marker degradation.

The 16-DPA intermediate is important to the synthesis of many other medically important steroids. A very similar approach can produce 16-DPA from solanine.²³¹

Soy semisynthesis

Progesterone can also be made from the stigmasterol found in soybean oil also. c.f. Percy Julian.

Total synthesis

A total synthesis of progesterone was reported in 1971 by W.S. Johnson.²³² The synthesis begins with reacting the phosphonium salt 7 with phenyl lithium to produce the phosphonium ylide 8. The ylide 8 is reacted with an aldehyde to produce the alkene 9. The ketal protecting groups of 9 are hydrolyzed to produce the diketone 10, which in turn is cyclized to form the cyclopentenone 11. The ketone of 11 is reacted with methyl lithium to yield the tertiary alcohol 12, which in turn is treated with acid to produce the tertiary cation 13. The key step of the synthesis is the π-cation cyclization of 13 in which the B-, C-, and D-rings of the steroid are simultaneously formed to produce 14. This step resembles the cationic cyclization reaction used in the biosynthesis of steroids and hence is referred to as biomimetic. In the next step the enol orthoester is hydrolyzed to produce the ketone 15. The cyclopentene A-ring is then opened by oxidizing with ozone to produce 16. Finally, the diketone 17 undergoes an intramolecular aldol condensation by treating with aqueous potassium hydroxide to produce progesterone.²³³

History

George W. Corner and Willard M. Allen discovered the hormonal action of progesterone in 1929.^234235236237 By 1931–1932, nearly pure crystalline material of high progestational activity had been isolated from the corpus luteum of animals, and by 1934, pure crystalline progesterone had been refined and obtained and the chemical structure of progesterone was determined.²³⁸²³⁹ This was achieved by Adolf Butenandt at the Chemisches Institut of Technical University in Danzig, who extracted this new compound from several thousand liters of urine.²⁴⁰

Chemical synthesis of progesterone from stigmasterol and pregnanediol was accomplished later that year.²⁴¹²⁴² Up to this point, progesterone, known generically as corpus luteum hormone, had been being referred to by several groups by different names, including corporin, lutein, luteosterone, and progestin.²⁴³²⁴⁴ In 1935, at the time of the Second International Conference on the Standardization of Sex Hormones in London, England, a compromise was made between the groups and the name progesterone (progestational steroidal ketone) was created.²⁴⁵²⁴⁶

Veterinary use

The use of progesterone tests in dog breeding to pinpoint ovulation is becoming more widely used. There are several tests available but the most reliable test is a blood test with blood drawn by a veterinarian and sent to a lab for processing. Results can usually be obtained with 24 to 72 hours. The rationale for using progesterone tests is that increased numbers begin in close proximity to preovulatory surge in gonadotrophins and continue through ovulation and estrus. When progesterone levels reach certain levels they can signal the stage of estrus the female is. Prediction of birth date of the pending litter can be very accurate if ovulation date is known. Puppies deliver with a day or two of 9 weeks gestation in most cases. It is not possible to determine pregnancy using progesterone tests once a breeding has taken place, however. This is due to the fact that, in dogs, progesterone levels remain elevated throughout the estrus period.²⁴⁷

Pricing

Pricing for progesterone can vary depending location, insurance coverage, discount coupons, quantity, shortages, manufacturers, brand or generic versions, different pharmacies, and so on. As of currently, 30 capsules of 100 mg of the generic version, Progesterone, from CVS Pharmacy is around $40 without any discounts or insurance applied. The brand version, Prometrium, is around $450 for 30 capsules without any discounts or insurance applied.²⁴⁸ In comparison, Walgreens offers 30 capsules of 100 mg in the generic version for $51 without insurance or coupons applied. The brand name costs around $431 for 30 capsules of 100 mg.²⁴⁹

•  This article incorporates text available under the CC BY-SA 3.0 license.

External links

• Progesterone MS Spectrum
• Progesterone at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
• Kimball JW (27 May 2007). "Progesterone". Kimball's Biology Pages. Archived from the original on 18 June 2008. Retrieved 18 June 2008.

References

1. Jameson JL, De Groot LJ (25 February 2015). Endocrinology: Adult and Pediatric E-Book. Elsevier Health Sciences. p. 2179. ISBN 978-0-323-32195-2. Archived from the original on 14 January 2023. Retrieved 29 October 2017. 978-0-323-32195-2 ↩

2. King TL, Brucker MC (25 October 2010). Pharmacology for Women's Health. Jones & Bartlett Publishers. pp. 372–373. ISBN 978-1-4496-5800-7. 978-1-4496-5800-7 ↩

3. King TL, Brucker MC (25 October 2010). Pharmacology for Women's Health. Jones & Bartlett Publishers. pp. 372–373. ISBN 978-1-4496-5800-7. 978-1-4496-5800-7 ↩

4. Baulieu E, Schumacher M (2000). "Progesterone as a neuroactive neurosteroid, with special reference to the effect of progesterone on myelination". Steroids. 65 (10–11): 605–612. doi:10.1016/s0039-128x(00)00173-2. PMID 11108866. S2CID 14952168. /wiki/Doi_(identifier) ↩

5. Prior JC (April 2019). "Progesterone Is Important for Transgender Women's Therapy-Applying Evidence for the Benefits of Progesterone in Ciswomen". The Journal of Clinical Endocrinology and Metabolism. 104 (4): 1181–1186. doi:10.1210/jc.2018-01777. PMID 30608551. S2CID 58620122. Evidence has accrued that normal progesterone (and ovulation), as well as physiological estradiol levels, is necessary during ciswomen's premenopausal menstrual cycles for current fertility and long-term health; transgender women may require progesterone therapy and similar potential physiological benefits https://doi.org/10.1210%2Fjc.2018-01777 ↩

6. Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 47X. ISBN 9783527607495. 9783527607495 ↩

7. King TL, Brucker MC (25 October 2010). Pharmacology for Women's Health. Jones & Bartlett Publishers. pp. 372–373. ISBN 978-1-4496-5800-7. 978-1-4496-5800-7 ↩

8. Josimovich JB (11 November 2013). Gynecologic Endocrinology. Springer Science & Business Media. pp. 9, 25–29. ISBN 978-1-4613-2157-6. Archived from the original on 14 January 2023. Retrieved 1 February 2016. 978-1-4613-2157-6 ↩

9. Thomas P, Pang Y (2012). "Membrane progesterone receptors: evidence for neuroprotective, neurosteroid signaling and neuroendocrine functions in neuronal cells". Neuroendocrinology. 96 (2): 162–171. doi:10.1159/000339822. PMC 3489003. PMID 22687885. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489003 ↩

10. Valadez-Cosmes P, Vázquez-Martínez ER, Cerbón M, Camacho-Arroyo I (October 2016). "Membrane progesterone receptors in reproduction and cancer". Molecular and Cellular Endocrinology. 434: 166–175. doi:10.1016/j.mce.2016.06.027. PMID 27368976. S2CID 3826650. /wiki/Doi_(identifier) ↩

11. Meyer C, Schmid R, Schmieding K, Falkenstein E, Wehling M (February 1998). "Characterization of high affinity progesterone-binding membrane proteins by anti-peptide antiserum". Steroids. 63 (2): 111–116. doi:10.1016/s0039-128x(97)00143-8. PMID 9516722. S2CID 40096058. /wiki/Doi_(identifier) ↩

12. Kabe Y, Handa H, Suematsu M (July 2018). "Function and structural regulation of the carbon monoxide (CO)-responsive membrane protein PGRMC1". Journal of Clinical Biochemistry and Nutrition. 63 (1): 12–17. doi:10.3164/jcbn.17-132. PMC 6064819. PMID 30087538. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6064819 ↩

13. Ryu CS, Klein K, Zanger UM (27 March 2017). "Membrane Associated Progesterone Receptors: Promiscuous Proteins with Pleiotropic Functions - Focus on Interactions with Cytochromes P450". Frontiers in Pharmacology. 8: 159. doi:10.3389/fphar.2017.00159. PMC 5366339. PMID 28396637. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5366339 ↩

14. Maurice T, Urani A, Phan VL, Romieu P (November 2001). "The interaction between neuroactive steroids and the sigma1 receptor function: behavioral consequences and therapeutic opportunities". Brain Research. Brain Research Reviews. 37 (1–3): 116–132. doi:10.1016/s0165-0173(01)00112-6. PMID 11744080. S2CID 44931783. /wiki/Doi_(identifier) ↩

15. Johannessen M, Fontanilla D, Mavlyutov T, Ruoho AE, Jackson MB (February 2011). "Antagonist action of progesterone at σ-receptors in the modulation of voltage-gated sodium channels". American Journal of Physiology. Cell Physiology. 300 (2): C328 – C337. doi:10.1152/ajpcell.00383.2010. PMC 3043630. PMID 21084640. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3043630 ↩

16. Baulieu E, Schumacher M (2000). "Progesterone as a neuroactive neurosteroid, with special reference to the effect of progesterone on myelination". Steroids. 65 (10–11): 605–612. doi:10.1016/s0039-128x(00)00173-2. PMID 11108866. S2CID 14952168. /wiki/Doi_(identifier) ↩

17. Rupprecht R, Reul JM, van Steensel B, Spengler D, Söder M, Berning B, et al. (October 1993). "Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands". European Journal of Pharmacology. 247 (2): 145–154. doi:10.1016/0922-4106(93)90072-H. PMID 8282004. /wiki/Doi_(identifier) ↩

18. Rupprecht R, Reul JM, van Steensel B, Spengler D, Söder M, Berning B, et al. (October 1993). "Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands". European Journal of Pharmacology. 247 (2): 145–154. doi:10.1016/0922-4106(93)90072-H. PMID 8282004. /wiki/Doi_(identifier) ↩

19. Elger W, Beier S, Pollow K, Garfield R, Shi SQ, Hillisch A (November 2003). "Conception and pharmacodynamic profile of drospirenone". Steroids. 68 (10–13): 891–905. doi:10.1016/j.steroids.2003.08.008. PMID 14667981. S2CID 41756726. /wiki/Doi_(identifier) ↩

20. Attardi BJ, Zeleznik A, Simhan H, Chiao JP, Mattison DR, Caritis SN (December 2007). "Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins". American Journal of Obstetrics and Gynecology. 197 (6): 599.e1–599.e7. doi:10.1016/j.ajog.2007.05.024. PMC 2278032. PMID 18060946. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2278032 ↩

21. Lei K, Chen L, Georgiou EX, Sooranna SR, Khanjani S, Brosens JJ, et al. (2012). "Progesterone acts via the nuclear glucocorticoid receptor to suppress IL-1β-induced COX-2 expression in human term myometrial cells". PLOS ONE. 7 (11): e50167. Bibcode:2012PLoSO...750167L. doi:10.1371/journal.pone.0050167. PMC 3509141. PMID 23209664. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509141 ↩

22. Paul SM, Purdy RH (March 1992). "Neuroactive steroids". FASEB Journal. 6 (6): 2311–2322. doi:10.1096/fasebj.6.6.1347506. PMID 1347506. S2CID 221753076. https://doi.org/10.1096%2Ffasebj.6.6.1347506 ↩

23. Kliewer SA, Goodwin B, Willson TM (October 2002). "The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism". Endocrine Reviews. 23 (5): 687–702. doi:10.1210/er.2001-0038. PMID 12372848. https://doi.org/10.1210%2Fer.2001-0038 ↩

24. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA (September 1998). "The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions". The Journal of Clinical Investigation. 102 (5): 1016–1023. doi:10.1172/JCI3703. PMC 508967. PMID 9727070. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC508967 ↩

25. Meanwell NA (8 December 2014). Tactics in Contemporary Drug Design. Springer. pp. 161–. ISBN 978-3-642-55041-6. Archived from the original on 14 January 2023. Retrieved 1 February 2016. 978-3-642-55041-6 ↩

26. Legato MJ, Bilezikian JP (2004). Principles of Gender-specific Medicine. Gulf Professional Publishing. pp. 146–. ISBN 978-0-12-440906-4. Archived from the original on 14 January 2023. Retrieved 1 February 2016. 978-0-12-440906-4 ↩

27. Williams DA (24 January 2012). "Drug Metabolism". In Lemke TL, Williams DA (eds.). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. p. 164. ISBN 978-1-60913-345-0. 978-1-60913-345-0 ↩

28. Estrogens—Advances in Research and Application: 2013 Edition: ScholarlyBrief. ScholarlyEditions. 21 June 2013. pp. 4–. ISBN 978-1-4816-7550-5. Archived from the original on 14 January 2023. Retrieved 1 February 2016. 978-1-4816-7550-5 ↩

29. Legato MJ, Bilezikian JP (2004). Principles of Gender-specific Medicine. Gulf Professional Publishing. pp. 146–. ISBN 978-0-12-440906-4. Archived from the original on 14 January 2023. Retrieved 1 February 2016. 978-0-12-440906-4 ↩

30. Strünker T, Goodwin N, Brenker C, Kashikar ND, Weyand I, Seifert R, Kaupp UB (March 2011). "The CatSper channel mediates progesterone-induced Ca2+ influx in human sperm". Nature. 471 (7338): 382–386. Bibcode:2011Natur.471..382S. doi:10.1038/nature09769. PMID 21412338. S2CID 4431334. /wiki/Bibcode_(identifier) ↩

31. Lishko PV, Botchkina IL, Kirichok Y (March 2011). "Progesterone activates the principal Ca2+ channel of human sperm". Nature. 471 (7338): 387–391. Bibcode:2011Natur.471..387L. doi:10.1038/nature09767. PMID 21412339. S2CID 4340309. /wiki/Bibcode_(identifier) ↩

32. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P (May 1990). "Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B". The EMBO Journal. 9 (5): 1603–1614. doi:10.1002/j.1460-2075.1990.tb08280.x. PMC 551856. PMID 2328727. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC551856 ↩

33. Cline JM, Wood CE (1 January 2006). Hallam SZ, Osuch JR (eds.). "Hormonal effects on the mammary gland of postmenopausal nonhuman primates". Breast Disease. 24. IOS Press: 59–70. doi:10.3233/bd-2006-24105. ISBN 978-1-58603-653-9. PMID 16917139. Archived from the original on 27 November 2023. Retrieved 2 August 2023. 978-1-58603-653-9 ↩

34. Johnson LR (2003). Essential Medical Physiology. Academic Press. p. 770. ISBN 978-0-12-387584-6. Archived from the original on 14 January 2023. Retrieved 1 February 2016. 978-0-12-387584-6 ↩

35. Coad J, Dunstall M (2011). Anatomy and Physiology for Midwives, with Pageburst online access,3: Anatomy and Physiology for Midwives. Elsevier Health Sciences. p. 413. ISBN 978-0-7020-3489-3. 978-0-7020-3489-3 ↩

36. Landau RL, Bergenstal DM, Lugibihl K, Kascht ME (October 1955). "The metabolic effects of progesterone in man". The Journal of Clinical Endocrinology and Metabolism. 15 (10): 1194–1215. doi:10.1210/jcem-15-10-1194. PMID 13263410. /wiki/Doi_(identifier) ↩

37. Masiutin M, Yadav M (2023). "Alternative androgen pathways". WikiJournal of Medicine. 10: X. doi:10.15347/WJM/2023.003. S2CID 257943362. https://doi.org/10.15347%2FWJM%2F2023.003 ↩

38. O'Shaughnessy PJ, Antignac JP, Le Bizec B, Morvan ML, Svechnikov K, Söder O, et al. (February 2019). "Alternative (backdoor) androgen production and masculinization in the human fetus". PLOS Biology. 17 (2): e3000002. doi:10.1371/journal.pbio.3000002. PMC 6375548. PMID 30763313. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375548 ↩

39. Flück CE, Pandey AV (May 2014). "Steroidogenesis of the testis -- new genes and pathways". Annales d'Endocrinologie. 75 (2): 40–47. doi:10.1016/j.ando.2014.03.002. PMID 24793988. /wiki/Doi_(identifier) ↩

40. Zachmann M (February 1996). "Prismatic cases: 17,20-desmolase (17,20-lyase) deficiency". The Journal of Clinical Endocrinology and Metabolism. 81 (2): 457–459. doi:10.1210/jcem.81.2.8636249. PMID 8636249. https://doi.org/10.1210%2Fjcem.81.2.8636249 ↩

41. Correia JN, Conner SJ, Kirkman-Brown JC (May 2007). "Non-genomic steroid actions in human spermatozoa. "Persistent tickling from a laden environment"". Seminars in Reproductive Medicine. 25 (3): 208–219. doi:10.1055/s-2007-973433. PMID 17447210. S2CID 260318879. /wiki/Doi_(identifier) ↩

42. Kirkman-Brown JC, Bray C, Stewart PM, Barratt CL, Publicover SJ (June 2000). "Biphasic elevation of [Ca(2+)](i) in individual human spermatozoa exposed to progesterone". Developmental Biology. 222 (2): 326–335. doi:10.1006/dbio.2000.9729. PMID 10837122. https://doi.org/10.1006%2Fdbio.2000.9729 ↩

43. Kirkman-Brown JC, Barratt CL, Publicover SJ (March 2004). "Slow calcium oscillations in human spermatozoa". The Biochemical Journal. 378 (Pt 3): 827–832. doi:10.1042/BJ20031368. PMC 1223996. PMID 14606954. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1223996 ↩

44. Harper CV, Barratt CL, Publicover SJ (October 2004). "Stimulation of human spermatozoa with progesterone gradients to simulate approach to the oocyte. Induction of [Ca(2+)](i) oscillations and cyclical transitions in flagellar beating". The Journal of Biological Chemistry. 279 (44): 46315–46325. doi:10.1074/jbc.M401194200. PMID 15322137. https://doi.org/10.1074%2Fjbc.M401194200 ↩

45. Marieb E (2013). Anatomy & physiology. Benjamin-Cummings. p. 903. ISBN 9780321887603. 9780321887603 ↩

46. Tosti E, Di Cosmo A, Cuomo A, Di Cristo C, Gragnaniello G (May 2001). "Progesterone induces activation in Octopus vulgaris spermatozoa". Molecular Reproduction and Development. 59 (1): 97–105. doi:10.1002/mrd.1011. PMID 11335951. S2CID 28390608. /wiki/Doi_(identifier) ↩

47. Bowen R (6 August 2000). "Placental Hormones". Archived from the original on 17 May 2007. Retrieved 12 March 2008. https://web.archive.org/web/20070517165244/http://www.vivo.colostate.edu/hbooks/pathphys/reprod/placenta/endocrine.html ↩

48. Patel B, Elguero S, Thakore S, Dahoud W, Bedaiwy M, Mesiano S (2014). "Role of nuclear progesterone receptor isoforms in uterine pathophysiology". Human Reproduction Update. 21 (2): 155–173. doi:10.1093/humupd/dmu056. PMC 4366574. PMID 25406186. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366574 ↩

49. Di Renzo GC, Giardina I, Clerici G, Brillo E, Gerli S (July 2016). "Progesterone in normal and pathological pregnancy". Hormone Molecular Biology and Clinical Investigation. 27 (1): 35–48. doi:10.1515/hmbci-2016-0038. PMID 27662646. S2CID 32239449. /wiki/Doi_(identifier) ↩

50. Bowen R (6 August 2000). "Placental Hormones". Archived from the original on 17 May 2007. Retrieved 12 March 2008. https://web.archive.org/web/20070517165244/http://www.vivo.colostate.edu/hbooks/pathphys/reprod/placenta/endocrine.html ↩

51. Di Renzo GC, Giardina I, Clerici G, Brillo E, Gerli S (July 2016). "Progesterone in normal and pathological pregnancy". Hormone Molecular Biology and Clinical Investigation. 27 (1): 35–48. doi:10.1515/hmbci-2016-0038. PMID 27662646. S2CID 32239449. /wiki/Doi_(identifier) ↩

52. Care A, Nevitt SJ, Medley N, Donegan S, Good L, Hampson L, et al. (February 2022). "Interventions to prevent spontaneous preterm birth in women with singleton pregnancy who are at high risk: systematic review and network meta-analysis". BMJ. 376: e064547. doi:10.1136/bmj-2021-064547. PMC 8845039. PMID 35168930. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8845039 ↩

53. O'Shaughnessy PJ, Antignac JP, Le Bizec B, Morvan ML, Svechnikov K, Söder O, et al. (February 2019). "Alternative (backdoor) androgen production and masculinization in the human fetus". PLOS Biology. 17 (2): e3000002. doi:10.1371/journal.pbio.3000002. PMC 6375548. PMID 30763313. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375548 ↩

54. Macias H, Hinck L (2012). "Mammary gland development". Wiley Interdisciplinary Reviews. Developmental Biology. 1 (4): 533–557. doi:10.1002/wdev.35. PMC 3404495. PMID 22844349. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404495 ↩

55. Cline JM, Wood CE (1 January 2006). Hallam SZ, Osuch JR (eds.). "Hormonal effects on the mammary gland of postmenopausal nonhuman primates". Breast Disease. 24. IOS Press: 59–70. doi:10.3233/bd-2006-24105. ISBN 978-1-58603-653-9. PMID 16917139. Archived from the original on 27 November 2023. Retrieved 2 August 2023. 978-1-58603-653-9 ↩

56. Johnson LR (2003). Essential Medical Physiology. Academic Press. p. 770. ISBN 978-0-12-387584-6. Archived from the original on 14 January 2023. Retrieved 1 February 2016. 978-0-12-387584-6 ↩

57. Coad J, Dunstall M (2011). Anatomy and Physiology for Midwives, with Pageburst online access,3: Anatomy and Physiology for Midwives. Elsevier Health Sciences. p. 413. ISBN 978-0-7020-3489-3. 978-0-7020-3489-3 ↩

58. Hilton HN, Graham JD, Clarke CL (September 2015). "Minireview: Progesterone Regulation of Proliferation in the Normal Human Breast and in Breast Cancer: A Tale of Two Scenarios?". Molecular Endocrinology. 29 (9): 1230–1242. doi:10.1210/me.2015-1152. PMC 5414684. PMID 26266959. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414684 ↩

59. Hilton HN, Graham JD, Clarke CL (September 2015). "Minireview: Progesterone Regulation of Proliferation in the Normal Human Breast and in Breast Cancer: A Tale of Two Scenarios?". Molecular Endocrinology. 29 (9): 1230–1242. doi:10.1210/me.2015-1152. PMC 5414684. PMID 26266959. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414684 ↩

60. Barbieri RL (13 September 2013). "The Breast". In Strauss JF, Barbieri RL (eds.). Yen and Jaffe's Reproductive Endocrinology. Elsevier Health Sciences. pp. 236–. ISBN 978-1-4557-2758-2. Archived from the original on 14 January 2023. Retrieved 1 February 2016. 978-1-4557-2758-2 ↩

61. Scaling AL, Prossnitz ER, Hathaway HJ (June 2014). "GPER mediates estrogen-induced signaling and proliferation in human breast epithelial cells and normal and malignant breast". Hormones & Cancer. 5 (3): 146–160. doi:10.1007/s12672-014-0174-1. PMC 4091989. PMID 24718936. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091989 ↩

62. Aupperlee MD, Leipprandt JR, Bennett JM, Schwartz RC, Haslam SZ (May 2013). "Amphiregulin mediates progesterone-induced mammary ductal development during puberty". Breast Cancer Research. 15 (3): R44. doi:10.1186/bcr3431. PMC 3738150. PMID 23705924. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738150 ↩

63. Aupperlee MD, Leipprandt JR, Bennett JM, Schwartz RC, Haslam SZ (May 2013). "Amphiregulin mediates progesterone-induced mammary ductal development during puberty". Breast Cancer Research. 15 (3): R44. doi:10.1186/bcr3431. PMC 3738150. PMID 23705924. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738150 ↩

64. Hilton HN, Graham JD, Clarke CL (September 2015). "Minireview: Progesterone Regulation of Proliferation in the Normal Human Breast and in Breast Cancer: A Tale of Two Scenarios?". Molecular Endocrinology. 29 (9): 1230–1242. doi:10.1210/me.2015-1152. PMC 5414684. PMID 26266959. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414684 ↩

65. Aupperlee MD, Leipprandt JR, Bennett JM, Schwartz RC, Haslam SZ (May 2013). "Amphiregulin mediates progesterone-induced mammary ductal development during puberty". Breast Cancer Research. 15 (3): R44. doi:10.1186/bcr3431. PMC 3738150. PMID 23705924. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738150 ↩

66. Aupperlee MD, Leipprandt JR, Bennett JM, Schwartz RC, Haslam SZ (May 2013). "Amphiregulin mediates progesterone-induced mammary ductal development during puberty". Breast Cancer Research. 15 (3): R44. doi:10.1186/bcr3431. PMC 3738150. PMID 23705924. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738150 ↩

67. Aupperlee MD, Leipprandt JR, Bennett JM, Schwartz RC, Haslam SZ (May 2013). "Amphiregulin mediates progesterone-induced mammary ductal development during puberty". Breast Cancer Research. 15 (3): R44. doi:10.1186/bcr3431. PMC 3738150. PMID 23705924. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738150 ↩

68. Kuhl H, Schneider HP (August 2013). "Progesterone--promoter or inhibitor of breast cancer". Climacteric. 16 (Suppl 1): 54–68. doi:10.3109/13697137.2013.768806. PMID 23336704. S2CID 20808536. /wiki/Doi_(identifier) ↩

69. Trabert B, Sherman ME, Kannan N, Stanczyk FZ (April 2020). "Progesterone and Breast Cancer". Endocrine Reviews. 41 (2): 320–344. doi:10.1210/endrev/bnz001. PMC 7156851. PMID 31512725. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156851 ↩

70. Collaborative Group on Hormonal Factors in Breast Cancer (September 2019). "Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence". Lancet. 394 (10204): 1159–1168. doi:10.1016/S0140-6736(19)31709-X. PMC 6891893. PMID 31474332. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6891893 ↩

71. Trabert B, Sherman ME, Kannan N, Stanczyk FZ (April 2020). "Progesterone and Breast Cancer". Endocrine Reviews. 41 (2): 320–344. doi:10.1210/endrev/bnz001. PMC 7156851. PMID 31512725. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156851 ↩

72. Stute P, Wildt L, Neulen J (April 2018). "The impact of micronized progesterone on breast cancer risk: a systematic review" (PDF). Climacteric. 21 (2): 111–122. doi:10.1080/13697137.2017.1421925. PMID 29384406. S2CID 3642971. Archived (PDF) from the original on 2 February 2024. Retrieved 2 February 2024. https://boris.unibe.ch/125894/1/29384406.pdf ↩

73. Asi N, Mohammed K, Haydour Q, Gionfriddo MR, Vargas OL, Prokop LJ, et al. (July 2016). "Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis". Systematic Reviews. 5 (1): 121. doi:10.1186/s13643-016-0294-5. PMC 4960754. PMID 27456847. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960754 ↩

74. Gompel A, Plu-Bureau G (August 2018). "Progesterone, progestins and the breast in menopause treatment". Climacteric. 21 (4): 326–332. doi:10.1080/13697137.2018.1476483. PMID 29852797. S2CID 46922084. /wiki/Doi_(identifier) ↩

75. Kuhl H, Schneider HP (August 2013). "Progesterone--promoter or inhibitor of breast cancer". Climacteric. 16 (Suppl 1): 54–68. doi:10.3109/13697137.2013.768806. PMID 23336704. S2CID 20808536. /wiki/Doi_(identifier) ↩

76. Davey DA (October 2018). "Menopausal hormone therapy: a better and safer future". Climacteric. 21 (5): 454–461. doi:10.1080/13697137.2018.1439915. PMID 29526116. S2CID 3850275. /wiki/Doi_(identifier) ↩

77. Trabert B, Sherman ME, Kannan N, Stanczyk FZ (April 2020). "Progesterone and Breast Cancer". Endocrine Reviews. 41 (2): 320–344. doi:10.1210/endrev/bnz001. PMC 7156851. PMID 31512725. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156851 ↩

78. Raine-Fenning NJ, Brincat MP, Muscat-Baron Y (2003). "Skin aging and menopause : implications for treatment". American Journal of Clinical Dermatology. 4 (6): 371–378. doi:10.2165/00128071-200304060-00001. PMID 12762829. S2CID 20392538. /wiki/Doi_(identifier) ↩

79. Holzer G, Riegler E, Hönigsmann H, Farokhnia S, Schmidt JB (September 2005). "Effects and side-effects of 2% progesterone cream on the skin of peri- and postmenopausal women: results from a double-blind, vehicle-controlled, randomized study". The British Journal of Dermatology. 153 (3): 626–634. doi:10.1111/j.1365-2133.2005.06685.x. PMID 16120154. S2CID 6077829. /wiki/Doi_(identifier) ↩

80. Raine-Fenning NJ, Brincat MP, Muscat-Baron Y (2003). "Skin aging and menopause : implications for treatment". American Journal of Clinical Dermatology. 4 (6): 371–378. doi:10.2165/00128071-200304060-00001. PMID 12762829. S2CID 20392538. /wiki/Doi_(identifier) ↩

81. Holzer G, Riegler E, Hönigsmann H, Farokhnia S, Schmidt JB (September 2005). "Effects and side-effects of 2% progesterone cream on the skin of peri- and postmenopausal women: results from a double-blind, vehicle-controlled, randomized study". The British Journal of Dermatology. 153 (3): 626–634. doi:10.1111/j.1365-2133.2005.06685.x. PMID 16120154. S2CID 6077829. /wiki/Doi_(identifier) ↩

82. Raine-Fenning NJ, Brincat MP, Muscat-Baron Y (2003). "Skin aging and menopause : implications for treatment". American Journal of Clinical Dermatology. 4 (6): 371–378. doi:10.2165/00128071-200304060-00001. PMID 12762829. S2CID 20392538. /wiki/Doi_(identifier) ↩

83. Holzer G, Riegler E, Hönigsmann H, Farokhnia S, Schmidt JB (September 2005). "Effects and side-effects of 2% progesterone cream on the skin of peri- and postmenopausal women: results from a double-blind, vehicle-controlled, randomized study". The British Journal of Dermatology. 153 (3): 626–634. doi:10.1111/j.1365-2133.2005.06685.x. PMID 16120154. S2CID 6077829. /wiki/Doi_(identifier) ↩

84. Raine-Fenning NJ, Brincat MP, Muscat-Baron Y (2003). "Skin aging and menopause : implications for treatment". American Journal of Clinical Dermatology. 4 (6): 371–378. doi:10.2165/00128071-200304060-00001. PMID 12762829. S2CID 20392538. /wiki/Doi_(identifier) ↩

85. Raine-Fenning NJ, Brincat MP, Muscat-Baron Y (2003). "Skin aging and menopause : implications for treatment". American Journal of Clinical Dermatology. 4 (6): 371–378. doi:10.2165/00128071-200304060-00001. PMID 12762829. S2CID 20392538. /wiki/Doi_(identifier) ↩

86. Raine-Fenning NJ, Brincat MP, Muscat-Baron Y (2003). "Skin aging and menopause : implications for treatment". American Journal of Clinical Dermatology. 4 (6): 371–378. doi:10.2165/00128071-200304060-00001. PMID 12762829. S2CID 20392538. /wiki/Doi_(identifier) ↩

87. Holzer G, Riegler E, Hönigsmann H, Farokhnia S, Schmidt JB (September 2005). "Effects and side-effects of 2% progesterone cream on the skin of peri- and postmenopausal women: results from a double-blind, vehicle-controlled, randomized study". The British Journal of Dermatology. 153 (3): 626–634. doi:10.1111/j.1365-2133.2005.06685.x. PMID 16120154. S2CID 6077829. /wiki/Doi_(identifier) ↩

88. Raine-Fenning NJ, Brincat MP, Muscat-Baron Y (2003). "Skin aging and menopause : implications for treatment". American Journal of Clinical Dermatology. 4 (6): 371–378. doi:10.2165/00128071-200304060-00001. PMID 12762829. S2CID 20392538. /wiki/Doi_(identifier) ↩

89. Holzer G, Riegler E, Hönigsmann H, Farokhnia S, Schmidt JB (September 2005). "Effects and side-effects of 2% progesterone cream on the skin of peri- and postmenopausal women: results from a double-blind, vehicle-controlled, randomized study". The British Journal of Dermatology. 153 (3): 626–634. doi:10.1111/j.1365-2133.2005.06685.x. PMID 16120154. S2CID 6077829. /wiki/Doi_(identifier) ↩

90. Raine-Fenning NJ, Brincat MP, Muscat-Baron Y (2003). "Skin aging and menopause : implications for treatment". American Journal of Clinical Dermatology. 4 (6): 371–378. doi:10.2165/00128071-200304060-00001. PMID 12762829. S2CID 20392538. /wiki/Doi_(identifier) ↩

91. Holzer G, Riegler E, Hönigsmann H, Farokhnia S, Schmidt JB (September 2005). "Effects and side-effects of 2% progesterone cream on the skin of peri- and postmenopausal women: results from a double-blind, vehicle-controlled, randomized study". The British Journal of Dermatology. 153 (3): 626–634. doi:10.1111/j.1365-2133.2005.06685.x. PMID 16120154. S2CID 6077829. /wiki/Doi_(identifier) ↩

92. Holzer G, Riegler E, Hönigsmann H, Farokhnia S, Schmidt JB (September 2005). "Effects and side-effects of 2% progesterone cream on the skin of peri- and postmenopausal women: results from a double-blind, vehicle-controlled, randomized study". The British Journal of Dermatology. 153 (3): 626–634. doi:10.1111/j.1365-2133.2005.06685.x. PMID 16120154. S2CID 6077829. /wiki/Doi_(identifier) ↩

93. Holzer G, Riegler E, Hönigsmann H, Farokhnia S, Schmidt JB (September 2005). "Effects and side-effects of 2% progesterone cream on the skin of peri- and postmenopausal women: results from a double-blind, vehicle-controlled, randomized study". The British Journal of Dermatology. 153 (3): 626–634. doi:10.1111/j.1365-2133.2005.06685.x. PMID 16120154. S2CID 6077829. /wiki/Doi_(identifier) ↩

94. King SR (9 November 2012). Neurosteroids and the Nervous System. Springer Science & Business Media. pp. 44–46. ISBN 978-1-4614-5559-2. 978-1-4614-5559-2 ↩

95. Fleischman DS, Fessler DM, Cholakians AE (July 2015). "Testing the Affiliation Hypothesis of Homoerotic Motivation in Humans: The Effects of Progesterone and Priming". Archives of Sexual Behavior. 44 (5): 1395–1404. doi:10.1007/s10508-014-0436-6. PMID 25420899. S2CID 9864224. Archived from the original on 23 September 2020. Retrieved 2 August 2023. https://researchportal.port.ac.uk/portal/en/publications/testing-the-affiliation-hypothesis-of-homoerotic-motivation-in-humans(d1eb5448-5664-4d2d-8694-18f970836cbb).html ↩

96. "Homosexuality may help us bond". UoP News. Archived from the original on 2 July 2019. Retrieved 2 July 2019. https://web.archive.org/web/20190702203503/https://uopnews.port.ac.uk/2014/11/25/homosexuality-may-help-us-bond/ ↩

97. "Having homosexual thoughts 'is an essential part of human evolution' study suggests". The Telegraph. 25 November 2014. Archived from the original on 15 February 2018. Retrieved 4 April 2018. https://www.telegraph.co.uk/news/science/11251206/Having-homosexual-thoughts-is-an-essential-part-of-human-evolution-study-suggests.html ↩

98. "New Study Identifies Evolutionary Basis Of Homosexuality". HuffPost. 26 November 2014. Archived from the original on 27 November 2023. Retrieved 21 October 2023. https://www.huffpost.com/entry/homosexuality-evolution-social-bonding_n_6218406 ↩

99. Hanukoglu I, Karavolas HJ, Goy RW (April 1977). "Progesterone metabolism in the pineal, brain stem, thalamus and corpus callosum of the female rat". Brain Research. 125 (2): 313–324. doi:10.1016/0006-8993(77)90624-2. PMID 558037. S2CID 35814845. Archived from the original on 5 March 2021. Retrieved 28 June 2019. https://zenodo.org/record/890908 ↩

100. Schumacher M, Guennoun R, Robert F, Carelli C, Gago N, Ghoumari A, et al. (June 2004). "Local synthesis and dual actions of progesterone in the nervous system: neuroprotection and myelination". Growth Hormone & IGF Research. 14 (Suppl A): S18 – S33. doi:10.1016/j.ghir.2004.03.007. PMID 15135772. /wiki/Doi_(identifier) ↩

101. Singh M, Su C, Ng S (September 2013). "Non-genomic mechanisms of progesterone action in the brain". Frontiers in Neuroscience. 7: 159. doi:10.3389/fnins.2013.00159. PMC 3776940. PMID 24065876. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776940 ↩

102. Roof RL, Hall ED (May 2000). "Gender differences in acute CNS trauma and stroke: neuroprotective effects of estrogen and progesterone". Journal of Neurotrauma. 17 (5): 367–388. doi:10.1089/neu.2000.17.367. PMID 10833057. /wiki/Doi_(identifier) ↩

103. Pan DS, Liu WG, Yang XF, Cao F (October 2007). "Inhibitory effect of progesterone on inflammatory factors after experimental traumatic brain injury". Biomedical and Environmental Sciences. 20 (5): 432–438. PMID 18188998. /wiki/PMID_(identifier) ↩

104. Jiang C, Zuo F, Wang Y, Wan J, Yang Z, Lu H, et al. (June 2016). "Progesterone exerts neuroprotective effects and improves long-term neurologic outcome after intracerebral hemorrhage in middle-aged mice". Neurobiology of Aging. 42: 13–24. doi:10.1016/j.neurobiolaging.2016.02.029. PMC 4857017. PMID 27143417. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4857017 ↩

105. Luoma JI, Stern CM, Mermelstein PG (August 2012). "Progesterone inhibition of neuronal calcium signaling underlies aspects of progesterone-mediated neuroprotection". The Journal of Steroid Biochemistry and Molecular Biology. 131 (1–2): 30–36. doi:10.1016/j.jsbmb.2011.11.002. PMC 3303940. PMID 22101209. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3303940 ↩

106. Stein DG (March 2008). "Progesterone exerts neuroprotective effects after brain injury". Brain Research Reviews. 57 (2): 386–397. doi:10.1016/j.brainresrev.2007.06.012. PMC 2699575. PMID 17826842. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699575 ↩

107. Espinoza TR, Wright DW (2011). "The role of progesterone in traumatic brain injury". The Journal of Head Trauma Rehabilitation. 26 (6): 497–499. doi:10.1097/HTR.0b013e31823088fa. PMC 6025750. PMID 22088981. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025750 ↩

108. Jiang C, Zuo F, Wang Y, Lu H, Yang Q, Wang J (January 2016). "Progesterone Changes VEGF and BDNF Expression and Promotes Neurogenesis After Ischemic Stroke". Molecular Neurobiology. 54 (1): 571–581. doi:10.1007/s12035-015-9651-y. PMC 4938789. PMID 26746666. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938789 ↩

109. Luoma JI, Stern CM, Mermelstein PG (August 2012). "Progesterone inhibition of neuronal calcium signaling underlies aspects of progesterone-mediated neuroprotection". The Journal of Steroid Biochemistry and Molecular Biology. 131 (1–2): 30–36. doi:10.1016/j.jsbmb.2011.11.002. PMC 3303940. PMID 22101209. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3303940 ↩

110. Herson PS, Koerner IP, Hurn PD (May 2009). "Sex, sex steroids, and brain injury". Seminars in Reproductive Medicine. 27 (3): 229–239. doi:10.1055/s-0029-1216276. PMC 2675922. PMID 19401954. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2675922 ↩

111. Stein DG (March 2008). "Progesterone exerts neuroprotective effects after brain injury". Brain Research Reviews. 57 (2): 386–397. doi:10.1016/j.brainresrev.2007.06.012. PMC 2699575. PMID 17826842. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699575 ↩

112. Stein DG (March 2008). "Progesterone exerts neuroprotective effects after brain injury". Brain Research Reviews. 57 (2): 386–397. doi:10.1016/j.brainresrev.2007.06.012. PMC 2699575. PMID 17826842. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699575 ↩

113. Li Z, Wang B, Kan Z, Zhang B, Yang Z, Chen J, et al. (January 2012). "Progesterone increases circulating endothelial progenitor cells and induces neural regeneration after traumatic brain injury in aged rats". Journal of Neurotrauma. 29 (2): 343–353. doi:10.1089/neu.2011.1807. PMC 3261789. PMID 21534727. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3261789 ↩

114. Lynch WJ, Sofuoglu M (December 2010). "Role of progesterone in nicotine addiction: evidence from initiation to relapse". Experimental and Clinical Psychopharmacology. 18 (6): 451–461. doi:10.1037/a0021265. PMC 3638762. PMID 21186920. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3638762 ↩

115. Cosgrove KP, Esterlis I, McKee SA, Bois F, Seibyl JP, Mazure CM, et al. (April 2012). "Sex differences in availability of β2*-nicotinic acetylcholine receptors in recently abstinent tobacco smokers". Archives of General Psychiatry. 69 (4): 418–427. doi:10.1001/archgenpsychiatry.2011.1465. PMC 3508698. PMID 22474108. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508698 ↩

116. Lynch WJ, Sofuoglu M (December 2010). "Role of progesterone in nicotine addiction: evidence from initiation to relapse". Experimental and Clinical Psychopharmacology. 18 (6): 451–461. doi:10.1037/a0021265. PMC 3638762. PMID 21186920. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3638762 ↩

117. Mello NK, Knudson IM, Kelly M, Fivel PA, Mendelson JH (October 2011). "Effects of progesterone and testosterone on cocaine self-administration and cocaine discrimination by female rhesus monkeys". Neuropsychopharmacology. 36 (11): 2187–2199. doi:10.1038/npp.2011.130. PMC 3176575. PMID 21796112. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3176575 ↩

118. Buser T (1 June 2012). "The impact of the menstrual cycle and hormonal contraceptives on competitiveness" (PDF). Journal of Economic Behavior & Organization. Gender Differences in Risk Aversion and Competition. 83 (1): 1–10. doi:10.1016/j.jebo.2011.06.006. ISSN 0167-2681. Archived (PDF) from the original on 2 February 2024. Retrieved 2 February 2024. https://pure.uva.nl/ws/files/1864146/117489_376503.pdf ↩

119. Sriram D (2007). Medicinal Chemistry. New Delhi: Dorling Kindersley India Pvt. Ltd. p. 432. ISBN 978-81-317-0031-0. 978-81-317-0031-0 ↩

120. Blackburn S (14 April 2014). Maternal, Fetal, & Neonatal Physiology. Elsevier Health Sciences. pp. 92–. ISBN 978-0-323-29296-2. 978-0-323-29296-2 ↩

121. Blackburn S (14 April 2014). Maternal, Fetal, & Neonatal Physiology. Elsevier Health Sciences. pp. 92–. ISBN 978-0-323-29296-2. 978-0-323-29296-2 ↩

122. Faivre EJ, Lange CA (January 2007). "Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells". Molecular and Cellular Biology. 27 (2): 466–480. doi:10.1128/MCB.01539-06. PMC 1800800. PMID 17074804. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1800800 ↩

123. Nosek TM. "Section 5/5ch9/s5ch9_13". Essentials of Human Physiology. Archived from the original on 24 March 2016. https://web.archive.org/web/20160324124828/http://humanphysiology.tuars.com/program/section5/5ch9/s5ch9_13.htm ↩

124. Rothchild I (1969), Salhanick HA, Kipnis DM, Wiele RL (eds.), "The Physiologic Basis for the Temperature Raising Effect of Progesterone", Metabolic Effects of Gonadal Hormones and Contraceptive Steroids, Boston, MA: Springer US, pp. 668–675, doi:10.1007/978-1-4684-1782-1_49, ISBN 978-1-4684-1782-1, archived from the original on 29 August 2021, retrieved 22 March 2021 978-1-4684-1782-1 ↩

125. Hould FS, Fried GM, Fazekas AG, Tremblay S, Mersereau WA (December 1988). "Progesterone receptors regulate gallbladder motility". The Journal of Surgical Research. 45 (6): 505–512. doi:10.1016/0022-4804(88)90137-0. PMID 3184927. /wiki/Doi_(identifier) ↩

126. "Hormones and Oral Health". WebMD. Archived from the original on 18 June 2016. Retrieved 22 July 2013. http://www.webmd.com/oral-health/hormones-oral-health ↩

127. Picard F, Wanatabe M, Schoonjans K, Lydon J, O'Malley BW, Auwerx J (November 2002). "Progesterone receptor knockout mice have an improved glucose homeostasis secondary to beta -cell proliferation". Proceedings of the National Academy of Sciences of the United States of America. 99 (24): 15644–15648. doi:10.1073/pnas.202612199. PMC 137770. PMID 12438645. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC137770 ↩

128. Brănişteanu DD, Mathieu C (March 2003). "Progesterone in gestational diabetes mellitus: guilty or not guilty?". Trends in Endocrinology and Metabolism. 14 (2): 54–56. doi:10.1016/S1043-2760(03)00003-1. PMID 12591170. S2CID 38209977. /wiki/Doi_(identifier) ↩

129. Whynott RM, Summers KM, Jakubiak M, Van Voorhis BJ, Mejia RB (June 2021). "The effect of weight and body mass index on serum progesterone values and live birth rate in cryopreserved in vitro fertilization cycles". F&S Reports. 2 (2): 195–200. doi:10.1016/j.xfre.2021.02.005. PMC 8267385. PMID 34278354. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267385 ↩

130. Kaemmle LM, Stadler A, Janka H, von Wolff M, Stute P (August 2022). "The impact of micronized progesterone on cardiovascular events - a systematic review". Climacteric. 25 (4): 327–336. doi:10.1080/13697137.2021.2022644. PMID 35112635. S2CID 246487187. /wiki/Doi_(identifier) ↩

131. Gasser S, Heidemeyer K, von Wolff M, Stute P (June 2021). "Impact of progesterone on skin and hair in menopause - a comprehensive review". Climacteric. 24 (3): 229–235. doi:10.1080/13697137.2020.1838476. PMID 33527841. S2CID 231757325. /wiki/Doi_(identifier) ↩

132. Javed AA, Mayhew AJ, Shea AK, Raina P (August 2019). "Association Between Hormone Therapy and Muscle Mass in Postmenopausal Women: A Systematic Review and Meta-analysis". JAMA Network Open. 2 (8): e1910154. doi:10.1001/jamanetworkopen.2019.10154. PMC 6716293. PMID 31461147. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6716293 ↩

133. Coquoz A, Gruetter C, Stute P (April 2019). "Impact of micronized progesterone on body weight, body mass index, and glucose metabolism: a systematic review". Climacteric. 22 (2): 148–161. doi:10.1080/13697137.2018.1514003. PMID 30477366. S2CID 53782622. /wiki/Doi_(identifier) ↩

134. Bewick PM (2002). Medicinal natural products: a biosynthetic approach. New York: Wiley. p. 244. ISBN 0-471-49641-3. 0-471-49641-3 ↩

135. Duport C, Spagnoli R, Degryse E, Pompon D (February 1998). "Self-sufficient biosynthesis of pregnenolone and progesterone in engineered yeast". Nature Biotechnology. 16 (2): 186–189. doi:10.1038/nbt0298-186. PMID 9487528. S2CID 852617. /wiki/Doi_(identifier) ↩

136. Zavod RM (24 January 2012). "Women's Health". In Lemke TL, Williams DA (eds.). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 1397–. ISBN 978-1-60913-345-0. Archived from the original on 14 January 2023. Retrieved 19 July 2018. 978-1-60913-345-0 ↩

137. Progesterone - Drugs.com, archived from the original on 27 March 2019, retrieved 23 August 2015 https://www.drugs.com/pro/progesterone.html ↩

138. Josimovich JB (11 November 2013). Gynecologic Endocrinology. Springer Science & Business Media. pp. 9, 25–29. ISBN 978-1-4613-2157-6. Archived from the original on 14 January 2023. Retrieved 1 February 2016. 978-1-4613-2157-6 ↩

139. Falcone T, Hurd WW (2007). Clinical Reproductive Medicine and Surgery. Elsevier Health Sciences. pp. 22–. ISBN 978-0-323-03309-1. Archived from the original on 10 January 2023. Retrieved 6 November 2016. 978-0-323-03309-1 ↩

140. Cupps PT (20 February 1991). Reproduction in Domestic Animals. Elsevier. pp. 101–. ISBN 978-0-08-057109-6. 978-0-08-057109-6 ↩

141. Stanczyk FZ (November 2003). "All progestins are not created equal". Steroids. 68 (10–13): 879–890. doi:10.1016/j.steroids.2003.08.003. PMID 14667980. S2CID 44601264. /wiki/Doi_(identifier) ↩

142. Hanukoglu I, Karavolas HJ, Goy RW (April 1977). "Progesterone metabolism in the pineal, brain stem, thalamus and corpus callosum of the female rat". Brain Research. 125 (2): 313–324. doi:10.1016/0006-8993(77)90624-2. PMID 558037. S2CID 35814845. Archived from the original on 5 March 2021. Retrieved 28 June 2019. https://zenodo.org/record/890908 ↩

143. Dowd FJ, Johnson B, Mariotti A (3 September 2016). Pharmacology and Therapeutics for Dentistry. Elsevier Health Sciences. pp. 448–. ISBN 978-0-323-44595-5. 978-0-323-44595-5 ↩

144. Falcone T, Hurd WW (2007). Clinical Reproductive Medicine and Surgery. Elsevier Health Sciences. pp. 22–. ISBN 978-0-323-03309-1. Archived from the original on 10 January 2023. Retrieved 6 November 2016. 978-0-323-03309-1 ↩

145. Stanczyk FZ (November 2003). "All progestins are not created equal". Steroids. 68 (10–13): 879–890. doi:10.1016/j.steroids.2003.08.003. PMID 14667980. S2CID 44601264. /wiki/Doi_(identifier) ↩

146. Kuhl H (August 2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration". Climacteric. 8 (Suppl 1): 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324. /wiki/Doi_(identifier) ↩

147. Stanczyk FZ (November 2003). "All progestins are not created equal". Steroids. 68 (10–13): 879–890. doi:10.1016/j.steroids.2003.08.003. PMID 14667980. S2CID 44601264. /wiki/Doi_(identifier) ↩

148. Hanukoglu I, Karavolas HJ, Goy RW (April 1977). "Progesterone metabolism in the pineal, brain stem, thalamus and corpus callosum of the female rat". Brain Research. 125 (2): 313–324. doi:10.1016/0006-8993(77)90624-2. PMID 558037. S2CID 35814845. Archived from the original on 5 March 2021. Retrieved 28 June 2019. https://zenodo.org/record/890908 ↩

149. Cupps PT (20 February 1991). Reproduction in Domestic Animals. Elsevier. pp. 101–. ISBN 978-0-08-057109-6. 978-0-08-057109-6 ↩

150. Stanczyk FZ (November 2003). "All progestins are not created equal". Steroids. 68 (10–13): 879–890. doi:10.1016/j.steroids.2003.08.003. PMID 14667980. S2CID 44601264. /wiki/Doi_(identifier) ↩

151. Plant TM, Zeleznik AJ (15 November 2014). Knobil and Neill's Physiology of Reproduction. Academic Press. pp. 304–. ISBN 978-0-12-397769-4. 978-0-12-397769-4 ↩

152. Santoro NF, Neal-Perry G (11 September 2010). Amenorrhea: A Case-Based, Clinical Guide. Springer Science & Business Media. pp. 13–. ISBN 978-1-60327-864-5. Archived from the original on 14 January 2023. Retrieved 6 November 2016. 978-1-60327-864-5 ↩

153. Reddy DS (2010). "Neurosteroids". Sex Differences in the Human Brain, their Underpinnings and Implications. Progress in Brain Research. Vol. 186. Elsevier. pp. 113–37. doi:10.1016/B978-0-444-53630-3.00008-7. ISBN 9780444536303. PMC 3139029. PMID 21094889. 9780444536303 ↩

154. Cupps PT (20 February 1991). Reproduction in Domestic Animals. Elsevier. pp. 101–. ISBN 978-0-08-057109-6. 978-0-08-057109-6 ↩

155. Stanczyk FZ (November 2003). "All progestins are not created equal". Steroids. 68 (10–13): 879–890. doi:10.1016/j.steroids.2003.08.003. PMID 14667980. S2CID 44601264. /wiki/Doi_(identifier) ↩

156. Plant TM, Zeleznik AJ (15 November 2014). Knobil and Neill's Physiology of Reproduction. Academic Press. pp. 304–. ISBN 978-0-12-397769-4. 978-0-12-397769-4 ↩

157. Cupps PT (20 February 1991). Reproduction in Domestic Animals. Elsevier. pp. 101–. ISBN 978-0-08-057109-6. 978-0-08-057109-6 ↩

158. Santoro NF, Neal-Perry G (11 September 2010). Amenorrhea: A Case-Based, Clinical Guide. Springer Science & Business Media. pp. 13–. ISBN 978-1-60327-864-5. Archived from the original on 14 January 2023. Retrieved 6 November 2016. 978-1-60327-864-5 ↩

159. Falcone T, Hurd WW (2007). Clinical Reproductive Medicine and Surgery. Elsevier Health Sciences. pp. 22–. ISBN 978-0-323-03309-1. Archived from the original on 10 January 2023. Retrieved 6 November 2016. 978-0-323-03309-1 ↩

160. Stanczyk FZ (November 2003). "All progestins are not created equal". Steroids. 68 (10–13): 879–890. doi:10.1016/j.steroids.2003.08.003. PMID 14667980. S2CID 44601264. /wiki/Doi_(identifier) ↩

161. Josimovich JB (11 November 2013). Gynecologic Endocrinology. Springer Science & Business Media. pp. 9, 25–29. ISBN 978-1-4613-2157-6. Archived from the original on 14 January 2023. Retrieved 1 February 2016. 978-1-4613-2157-6 ↩

162. Baulieu E, Kelly PA (30 November 1990). Hormones: From Molecules to Disease. Springer Science & Business Media. pp. 401–. ISBN 978-0-412-02791-8. 978-0-412-02791-8 ↩

163. Josimovich JB (11 November 2013). Gynecologic Endocrinology. Springer Science & Business Media. pp. 9, 25–29. ISBN 978-1-4613-2157-6. Archived from the original on 14 January 2023. Retrieved 1 February 2016. 978-1-4613-2157-6 ↩

164. Stanczyk FZ (November 2003). "All progestins are not created equal". Steroids. 68 (10–13): 879–890. doi:10.1016/j.steroids.2003.08.003. PMID 14667980. S2CID 44601264. /wiki/Doi_(identifier) ↩

165. Baulieu E, Kelly PA (30 November 1990). Hormones: From Molecules to Disease. Springer Science & Business Media. pp. 401–. ISBN 978-0-412-02791-8. 978-0-412-02791-8 ↩

166. Beranič N, Gobec S, Rižner TL (May 2011). "Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3". Chemico-Biological Interactions. 191 (1–3): 227–233. Bibcode:2011CBI...191..227B. doi:10.1016/j.cbi.2010.12.012. PMID 21182831. /wiki/Bibcode_(identifier) ↩

167. Stanczyk FZ (November 2003). "All progestins are not created equal". Steroids. 68 (10–13): 879–890. doi:10.1016/j.steroids.2003.08.003. PMID 14667980. S2CID 44601264. /wiki/Doi_(identifier) ↩

168. Anderson GD, Odegard PS (October 2004). "Pharmacokinetics of estrogen and progesterone in chronic kidney disease". Advances in Chronic Kidney Disease. 11 (4): 357–360. doi:10.1053/j.ackd.2004.07.001. PMID 15492972. /wiki/Doi_(identifier) ↩

169. Kuhl H (August 2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration". Climacteric. 8 (Suppl 1): 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324. /wiki/Doi_(identifier) ↩

170. Greenblatt JM, Brogan K (27 April 2016). Integrative Therapies for Depression: Redefining Models for Assessment, Treatment and Prevention. CRC Press. pp. 201–. ISBN 978-1-4987-0230-0. 978-1-4987-0230-0 ↩

171. Graham C (2 December 2012). Reproductive Biology of the Great Apes: Comparative and Biomedical Perspectives. Elsevier. pp. 179–. ISBN 978-0-323-14971-6. Archived from the original on 14 January 2023. Retrieved 6 November 2016. 978-0-323-14971-6 ↩

172. Strushkevich N, Gilep AA, Shen L, Arrowsmith CH, Edwards AM, Usanov SA, Park HW (February 2013). "Structural insights into aldosterone synthase substrate specificity and targeted inhibition". Molecular Endocrinology. 27 (2): 315–324. doi:10.1210/me.2012-1287. PMC 5417327. PMID 23322723. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5417327 ↩

173. van Rooyen D, Gent R, Barnard L, Swart AC (April 2018). "The in vitro metabolism of 11β-hydroxyprogesterone and 11-ketoprogesterone to 11-ketodihydrotestosterone in the backdoor pathway". The Journal of Steroid Biochemistry and Molecular Biology. 178: 203–212. doi:10.1016/j.jsbmb.2017.12.014. PMID 29277707. S2CID 3700135. /wiki/Doi_(identifier) ↩

174. Masiutin M, Yadav M (2023). "Alternative androgen pathways". WikiJournal of Medicine. 10: X. doi:10.15347/WJM/2023.003. S2CID 257943362. https://doi.org/10.15347%2FWJM%2F2023.003 ↩

175. de Azevedo Piccinato C (2008). Regulation of Steroid Metabolism and the Hepatic Transcriptome by Estradiol and Progesterone. pp. 24–25. ISBN 978-1-109-04632-8.[permanent dead link] 978-1-109-04632-8 ↩

176. de Azevedo Piccinato C (2008). Regulation of Steroid Metabolism and the Hepatic Transcriptome by Estradiol and Progesterone. pp. 24–25. ISBN 978-1-109-04632-8.[permanent dead link] 978-1-109-04632-8 ↩

177. Stanczyk FZ (November 2003). "All progestins are not created equal". Steroids. 68 (10–13): 879–890. doi:10.1016/j.steroids.2003.08.003. PMID 14667980. S2CID 44601264. /wiki/Doi_(identifier) ↩

178. Akalin S (January 1991). "Effects of ketoconazole in hirsute women". Acta Endocrinologica. 124 (1): 19–22. doi:10.1530/acta.0.1240019. PMID 1825737. S2CID 9831739. /wiki/Doi_(identifier) ↩

179. Aufrère MB, Benson H (June 1976). "Progesterone: an overview and recent advances". Journal of Pharmaceutical Sciences. 65 (6): 783–800. doi:10.1002/jps.2600650602. PMID 945344. /wiki/Doi_(identifier) ↩

180. Csapo AI, Pulkkinen MO, Wiest WG (March 1973). "Effects of luteectomy and progesterone replacement therapy in early pregnant patients". American Journal of Obstetrics and Gynecology. 115 (6): 759–765. doi:10.1016/0002-9378(73)90517-6. PMID 4688578. /wiki/Doi_(identifier) ↩

181. NIH Clinical Center (16 August 2004). "Progesterone Historical Reference Ranges". United States National Institutes of Health. Archived from the original on 9 January 2009. Retrieved 12 March 2008. https://web.archive.org/web/20090109072721/http://cclnprod.cc.nih.gov/dlm/testguide.nsf/Index/CB26894E1EB28DEF85256BA5005B000E?OpenDocument ↩

182. Aufrère MB, Benson H (June 1976). "Progesterone: an overview and recent advances". Journal of Pharmaceutical Sciences. 65 (6): 783–800. doi:10.1002/jps.2600650602. PMID 945344. /wiki/Doi_(identifier) ↩

183. Chernecky CC, Berger BJ (31 October 2012). Laboratory Tests and Diagnostic Procedures - E-Book. Elsevier Health Sciences. pp. 908–. ISBN 978-1-4557-4502-9. Archived from the original on 27 February 2024. Retrieved 23 August 2023. 978-1-4557-4502-9 ↩

184. Becker KL (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. pp. 889, 940. ISBN 978-0-7817-1750-2. Archived from the original on 27 February 2024. Retrieved 23 August 2023. 978-0-7817-1750-2 ↩

185. Josimovich JB (11 November 2013). Gynecologic Endocrinology. Springer Science & Business Media. pp. 9, 25–29, 139. ISBN 978-1-4613-2157-6. Archived from the original on 14 January 2023. Retrieved 1 February 2016. 978-1-4613-2157-6 ↩

186. van Keep P, Utian W (6 December 2012). The Premenstrual Syndrome: Proceedings of a workshop held during the Sixth International Congress of Psychosomatic Obstetrics and Gynecology, Berlin, September 1980. Springer Science & Business Media. pp. 51–52. ISBN 978-94-011-6255-5. Archived from the original on 14 January 2023. Retrieved 1 February 2016. 978-94-011-6255-5 ↩

187. Strauss JF, Barbieri RL (2009). Yen and Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management. Elsevier Health Sciences. pp. 807–. ISBN 978-1-4160-4907-4. Archived from the original on 10 January 2023. Retrieved 23 August 2023. 978-1-4160-4907-4 ↩

188. Bajaj L, Berman S (1 January 2011). Berman's Pediatric Decision Making. Elsevier Health Sciences. pp. 160–. ISBN 978-0-323-05405-8. Archived from the original on 11 January 2023. Retrieved 23 August 2023. 978-0-323-05405-8 ↩

189. Lauritzen C (1988). "Natürliche und Synthetische Sexualhormone – Biologische Grundlagen und Behandlungsprinzipien" [Natural and Synthetic Sexual Hormones – Biological Basis and Medical Treatment Principles]. In Hermann P. G. Schneider, Christian Lauritzen, Eberhard Nieschlag (eds.). Grundlagen und Klinik der Menschlichen Fortpflanzung [Foundations and Clinic of Human Reproduction] (in German). Walter de Gruyter. pp. 229–306. ISBN 978-3110109689. OCLC 35483492. Archived from the original on 1 October 2023. Retrieved 23 August 2023. 978-3110109689 ↩

190. Little, A. B., & Billiar, R. B. (1983). Progestagens. In Endocrinology of Pregnancy, 3rd Edition (pp. 92–111). Harper and Row Philadelphia. https://scholar.google.com/scholar?cluster=2512291948467467634 Archived 22 February 2022 at the Wayback Machine https://scholar.google.com/scholar?cluster=2512291948467467634 ↩

191. Progesterone Reference Ranges, Performed at the Clinical Center at the National Institutes of Health, Bethesda MD, 03Feb09 https://web.archive.org/web/20150701024923/http://cclnprod.cc.nih.gov/dlm/testguide.nsf/0/CB26894E1EB28DEF85256BA5005B000E?OpenDocument ↩

192. Progesterone Reference Ranges, Performed at the Clinical Center at the National Institutes of Health, Bethesda MD, 03Feb09 https://web.archive.org/web/20150701024923/http://cclnprod.cc.nih.gov/dlm/testguide.nsf/0/CB26894E1EB28DEF85256BA5005B000E?OpenDocument ↩

193. Converted from mass values using molar mass of 314.46 g/mol ↩

194. Converted from mass values using molar mass of 314.46 g/mol ↩

195. Progesterone Reference Ranges, Performed at the Clinical Center at the National Institutes of Health, Bethesda MD, 03Feb09 https://web.archive.org/web/20150701024923/http://cclnprod.cc.nih.gov/dlm/testguide.nsf/0/CB26894E1EB28DEF85256BA5005B000E?OpenDocument ↩

196. Progesterone Reference Ranges, Performed at the Clinical Center at the National Institutes of Health, Bethesda MD, 03Feb09 https://web.archive.org/web/20150701024923/http://cclnprod.cc.nih.gov/dlm/testguide.nsf/0/CB26894E1EB28DEF85256BA5005B000E?OpenDocument ↩

197. Converted from mass values using molar mass of 314.46 g/mol ↩

198. Converted from mass values using molar mass of 314.46 g/mol ↩

199. Progesterone Reference Ranges, Performed at the Clinical Center at the National Institutes of Health, Bethesda MD, 03Feb09 https://web.archive.org/web/20150701024923/http://cclnprod.cc.nih.gov/dlm/testguide.nsf/0/CB26894E1EB28DEF85256BA5005B000E?OpenDocument ↩

200. Progesterone Reference Ranges, Performed at the Clinical Center at the National Institutes of Health, Bethesda MD, 03Feb09 https://web.archive.org/web/20150701024923/http://cclnprod.cc.nih.gov/dlm/testguide.nsf/0/CB26894E1EB28DEF85256BA5005B000E?OpenDocument ↩

201. Converted from mass values using molar mass of 314.46 g/mol ↩

202. Converted from mass values using molar mass of 314.46 g/mol ↩

203. Progesterone Reference Ranges, Performed at the Clinical Center at the National Institutes of Health, Bethesda MD, 03Feb09 https://web.archive.org/web/20150701024923/http://cclnprod.cc.nih.gov/dlm/testguide.nsf/0/CB26894E1EB28DEF85256BA5005B000E?OpenDocument ↩

204. Progesterone Reference Ranges, Performed at the Clinical Center at the National Institutes of Health, Bethesda MD, 03Feb09 https://web.archive.org/web/20150701024923/http://cclnprod.cc.nih.gov/dlm/testguide.nsf/0/CB26894E1EB28DEF85256BA5005B000E?OpenDocument ↩

205. Progesterone Reference Ranges, Performed at the Clinical Center at the National Institutes of Health, Bethesda MD, 03Feb09 https://web.archive.org/web/20150701024923/http://cclnprod.cc.nih.gov/dlm/testguide.nsf/0/CB26894E1EB28DEF85256BA5005B000E?OpenDocument ↩

206. Converted from mass values using molar mass of 314.46 g/mol ↩

207. Converted from mass values using molar mass of 314.46 g/mol ↩

208. Goodson III WH, Handagama P, Moore II DH, Dairkee S (13 December 2007). "Milk products are a source of dietary progesterone". 30th Annual San Antonio Breast Cancer Symposium. pp. abstract # 2028. Archived from the original on 20 September 2008. Retrieved 12 March 2008. https://www.docguide.com/news/content.nsf/news/852571020057CCF6852573B1007803AD ↩

209. Pauli GF, Friesen JB, Gödecke T, Farnsworth NR, Glodny B (March 2010). "Occurrence of progesterone and related animal steroids in two higher plants". Journal of Natural Products. 73 (3): 338–345. Bibcode:2010JNAtP..73..338P. doi:10.1021/np9007415. PMID 20108949. S2CID 26467578. /wiki/Bibcode_(identifier) ↩

210. Applezweig N (May 1969). "Steroids". Chemical Week. 104: 57–72. PMID 12255132. /wiki/PMID_(identifier) ↩

211. Noguchi E, Fujiwara Y, Matsushita S, Ikeda T, Ono M, Nohara T (September 2006). "Metabolism of tomato steroidal glycosides in humans". Chemical & Pharmaceutical Bulletin. 54 (9): 1312–1314. doi:10.1248/cpb.54.1312. PMID 16946542. https://doi.org/10.1248%2Fcpb.54.1312 ↩

212. Yang DJ, Lu TJ, Hwang LS (October 2003). "Isolation and identification of steroidal saponins in Taiwanese yam cultivar (Dioscorea pseudojaponica Yamamoto)" (PDF). Journal of Agricultural and Food Chemistry. 51 (22): 6438–6444. Bibcode:2003JAFC...51.6438Y. doi:10.1021/jf030390j. PMID 14558759. Archived (PDF) from the original on 3 August 2022. Retrieved 2 April 2022. http://ntur.lib.ntu.edu.tw/bitstream/246246/189462/1/58.pdf ↩

213. "Final report of the amended safety assessment of Dioscorea Villosa (Wild Yam) root extract". International Journal of Toxicology. 23 (Suppl 2): 49–54. 2004. doi:10.1080/10915810490499055. PMID 15513824. S2CID 962216. https://doi.org/10.1080%2F10915810490499055 ↩

214. Niño J, Jiménez DA, Mosquera OM, Correa YM (2007). "Diosgenin quantification by HPLC in a Dioscorea polygonoides tuber collection from colombian flora". Journal of the Brazilian Chemical Society. 18 (5): 1073–1076. doi:10.1590/S0103-50532007000500030. S2CID 95193700. https://doi.org/10.1590%2FS0103-50532007000500030 ↩

215. Myoda T, Nagai T, Nagashima T (2005). "Properties of starches in yam (Dioscorea spp.) tuber". Current Topics in Food Science and Technology: 105–114. ISBN 81-308-0003-9. 81-308-0003-9 ↩

216. Kuhl H (August 2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration". Climacteric. 8 (Suppl 1): 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324. /wiki/Doi_(identifier) ↩

217. Wesp LM, Deutsch MB (March 2017). "Hormonal and Surgical Treatment Options for Transgender Women and Transfeminine Spectrum Persons". The Psychiatric Clinics of North America. 40 (1): 99–111. doi:10.1016/j.psc.2016.10.006. PMID 28159148. /wiki/Doi_(identifier) ↩

218. Dolitsky SN, Cordeiro Mitchell CN, Stadler SS, Segars JH (November 2020). "Efficacy of progestin-only treatment for the management of menopausal symptoms: a systematic review". Menopause. 28 (2): 217–224. doi:10.1097/GME.0000000000001676. PMID 33109992. S2CID 225100434. /wiki/Doi_(identifier) ↩

219. Ruan X, Mueck AO (November 2014). "Systemic progesterone therapy--oral, vaginal, injections and even transdermal?". Maturitas. 79 (3): 248–255. doi:10.1016/j.maturitas.2014.07.009. PMID 25113944. /wiki/Doi_(identifier) ↩

220. Filicori M (November 2015). "Clinical roles and applications of progesterone in reproductive medicine: an overview". Acta Obstetricia et Gynecologica Scandinavica. 94 (Suppl 161): 3–7. doi:10.1111/aogs.12791. PMID 26443945. https://doi.org/10.1111%2Faogs.12791 ↩

221. Ciampaglia W, Cognigni GE (November 2015). "Clinical use of progesterone in infertility and assisted reproduction". Acta Obstetricia et Gynecologica Scandinavica. 94 (Suppl 161): 17–27. doi:10.1111/aogs.12770. PMID 26345161. S2CID 40753277. https://doi.org/10.1111%2Faogs.12770 ↩

222. Choi SJ (September 2017). "Use of progesterone supplement therapy for prevention of preterm birth: review of literatures". Obstetrics & Gynecology Science. 60 (5): 405–420. doi:10.5468/ogs.2017.60.5.405. PMC 5621069. PMID 28989916. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5621069 ↩

223. Coomarasamy A, Harb HM, Devall AJ, Cheed V, Roberts TE, Goranitis I, et al. (June 2020). "Progesterone to prevent miscarriage in those with early pregnancy bleeding: the PRISM RCT". Health Technology Assessment. 24 (33): 1–70. doi:10.3310/hta24330. PMC 7355406. PMID 32609084. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355406 ↩

224. Kuhl H (August 2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration". Climacteric. 8 (Suppl 1): 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324. /wiki/Doi_(identifier) ↩

225. Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 1024–. ISBN 978-1-4757-2085-3. 978-1-4757-2085-3 ↩

226. Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 880–. ISBN 978-3-88763-075-1. 978-3-88763-075-1 ↩

227. Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 1024–. ISBN 978-1-4757-2085-3. 978-1-4757-2085-3 ↩

228. Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 880–. ISBN 978-3-88763-075-1. 978-3-88763-075-1 ↩

229. Numazawa M, Nagaoka M, Kunitama Y (September 1986). "Regiospecific deoxygenation of the dihydroxyacetone moiety at C-17 of corticoid steroids with iodotrimethylsilane". Chemical & Pharmaceutical Bulletin. 34 (9): 3722–3726. doi:10.1248/cpb.34.3722. PMID 3815593. https://doi.org/10.1248%2Fcpb.34.3722 ↩

230. Marker RE, Krueger J (1940). "Sterols. CXII. Sapogenins. XLI. The Preparation of Trillin and its Conversion to Progesterone". J. Am. Chem. Soc. 62 (12): 3349–3350. Bibcode:1940JAChS..62.3349M. doi:10.1021/ja01869a023. /wiki/Bibcode_(identifier) ↩

231. Goswami A, Kotoky R, Rastogi RC, Ghosh AC (1 May 2003). "A One-Pot Efficient Process for 16-Dehydropregnenolone Acetate". Organic Process Research & Development. 7 (3): 306–308. doi:10.1021/op0200625. /wiki/Doi_(identifier) ↩

232. Johnson WS, Gravestock MB, McCarry BE (August 1971). "Acetylenic bond participation in biogenetic-like olefinic cyclizations. II. Synthesis of dl-progesterone". Journal of the American Chemical Society. 93 (17): 4332–4334. Bibcode:1971JAChS..93.4332J. doi:10.1021/ja00746a062. PMID 5131151. /wiki/Bibcode_(identifier) ↩

233. Johnson WS, Gravestock MB, McCarry BE (August 1971). "Acetylenic bond participation in biogenetic-like olefinic cyclizations. II. Synthesis of dl-progesterone". Journal of the American Chemical Society. 93 (17): 4332–4334. Bibcode:1971JAChS..93.4332J. doi:10.1021/ja00746a062. PMID 5131151. /wiki/Bibcode_(identifier) ↩

234. Josimovich JB (11 November 2013). Gynecologic Endocrinology. Springer Science & Business Media. pp. 9, 25–29. ISBN 978-1-4613-2157-6. Archived from the original on 14 January 2023. Retrieved 1 February 2016. 978-1-4613-2157-6 ↩

235. Corner GW, Allen WM (1 March 1929). "Physiology of the corpus luteum". American Journal of Physiology. Legacy Content. 88 (2): 326–339. doi:10.1152/ajplegacy.1929.88.2.326. ISSN 0002-9513. Archived from the original on 12 August 2021. Retrieved 12 August 2021. https://journals.physiology.org/doi/abs/10.1152/ajplegacy.1929.88.2.326 ↩

236. Coutinho EM, Segal SJ (1999). Is Menstruation Obsolete?. Oxford University Press. pp. 31–. ISBN 978-0-19-513021-8. Archived from the original on 14 January 2023. Retrieved 5 October 2016. 978-0-19-513021-8 ↩

237. Walker A (7 March 2008). The Menstrual Cycle. Routledge. pp. 49–. ISBN 978-1-134-71411-7. 978-1-134-71411-7 ↩

238. Josimovich JB (11 November 2013). Gynecologic Endocrinology. Springer Science & Business Media. pp. 9, 25–29. ISBN 978-1-4613-2157-6. Archived from the original on 14 January 2023. Retrieved 1 February 2016. 978-1-4613-2157-6 ↩

239. Coutinho EM, Segal SJ (1999). Is Menstruation Obsolete?. Oxford University Press. pp. 31–. ISBN 978-0-19-513021-8. Archived from the original on 14 January 2023. Retrieved 5 October 2016. 978-0-19-513021-8 ↩

240. Piosik R (2003). "Adolf Butenandt und sein Wirken an der Technischen Hochschule Danzig". CHEMKON. 10 (3): 135–138. doi:10.1002/ckon.200390038. /wiki/Doi_(identifier) ↩

241. Coutinho EM, Segal SJ (1999). Is Menstruation Obsolete?. Oxford University Press. pp. 31–. ISBN 978-0-19-513021-8. Archived from the original on 14 January 2023. Retrieved 5 October 2016. 978-0-19-513021-8 ↩

242. Ginsburg B (6 December 2012). Premenstrual Syndrome: Ethical and Legal Implications in a Biomedical Perspective. Springer Science & Business Media. pp. 274–. ISBN 978-1-4684-5275-4. Archived from the original on 14 January 2023. Retrieved 5 October 2016. 978-1-4684-5275-4 ↩

243. Josimovich JB (11 November 2013). Gynecologic Endocrinology. Springer Science & Business Media. pp. 9, 25–29. ISBN 978-1-4613-2157-6. Archived from the original on 14 January 2023. Retrieved 1 February 2016. 978-1-4613-2157-6 ↩

244. Rolleston HD (1936). The Endocrine Organs in Health and Disease: With an Historical Review. Oxford University Press, H. Milford. p. 406. Archived from the original on 14 January 2023. Retrieved 5 October 2016. https://books.google.com/books?id=tkgbAAAAIAAJ ↩

245. Josimovich JB (11 November 2013). Gynecologic Endocrinology. Springer Science & Business Media. pp. 9, 25–29. ISBN 978-1-4613-2157-6. Archived from the original on 14 January 2023. Retrieved 1 February 2016. 978-1-4613-2157-6 ↩

246. Allen WM (October 1970). "Progesterone: how did the name originate?". Southern Medical Journal. 63 (10): 1151–1155. doi:10.1097/00007611-197010000-00012. PMID 4922128. S2CID 35867375. /wiki/Doi_(identifier) ↩

247. Refsal K (February 2009). "Interpretation of Serum Progesterone Results for Management of Breeding in Dogs" (PDF). Webcd.endo.ref. Archived from the original on 29 August 2021. Retrieved 26 February 2018. https://www.dcpah.msu.edu/sections/endocrinology/Progesterone_Guidelines.pdf ↩

248. "Progesterone Prices, Coupons & Savings Tips - GoodRx". www.goodrx.com. Archived from the original on 30 March 2023. Retrieved 1 August 2023. https://www.goodrx.com/progesterone ↩

249. "Progesterone Prices, Coupons & Savings Tips - GoodRx". www.goodrx.com. Archived from the original on 30 March 2023. Retrieved 1 August 2023. https://www.goodrx.com/progesterone ↩